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ABSTRACT
Association of Incident Cancer to Low-Value Care and Healthcare Cost Burden
Among Elderly Medicare Beneficiaries
Chibuzo Iloabuchi
In the United States (US), 25% of healthcare spending is considered wasteful because it is spent
reimbursing low-value care. Low-value care is the utilization of healthcare services, medical
tests, and procedures that have unclear or no clinical benefit to patients but still exposes them to
risk. World-wide, low-value care imposes a significant economic burden on patients, payers,
governments, and society. Cancer care among older adults > 65 years is one of the biggest
drivers of healthcare expenditure in the US and accounts for nearly 40% of all spending, and
low-value care among cancer patients is prevalent and contributes to the financial toxicity of
cancer treatment. To date, no study has examined the risk of low-value non-cancer care among
patients with cancer. There is a critical need to assess the prevalence of low-value non-cancer
care in patients diagnosed with cancer and the risk factors associated with the receipt of lowvalue care. To fill the knowledge gap, the three related aims of this dissertation were (1) To
assess the association of incident cancer (breast, prostate, colorectal, and Non-Hodgkin’s
lymphoma) to low-value non-cancer care among older Medicare beneficiaries using machine
learning methods. (2) To assess the association of incident cancer (breast, colorectal, prostate,
ovarian, uterine, and Non-Hodgkin’s lymphoma) to annual wellness visit utilization among older
adults using machine learning methods. (3) To examine the association of low-value care to
economic burden (out-of-pocket expenditure) of older cancer survivors (breast, prostate,
colorectal, and Non-Hodgkin’s lymphoma) using machine-learning methods. The study used a
retrospective cohort study design, leveraging multiple years (2005-2015) of the cancer registry
data from the Surveillance, Epidemiology and End Results (SEER) program linked with the
Medicare claims data, the American community survey census tract files, and the Area Health
Resource Files. In the first aim, among elderly Medicare beneficiaries with incident breast,
colorectal, prostate cancers, and non-Hodgkin’s lymphoma (N = 329,267) the rates of low-value
care differed significantly by cancer type; the highest rates were observed in Non-Hodgkin’s
lymphoma (34%) followed by colorectal cancer (29% ) while the lowest rates were among
patients diagnosed with prostate cancer (22%). The most used low-value care services were
population-based screening for detection of carotid artery disease (10%), low-value MRI for low
back pain (9.8%), traction for low back pain (5%); the association of cancer to low-value care
varied by cancer type; both colorectal cancer and NHL were positively associated with low-value
care, but breast and prostate cancers were negatively associated with low-value care. In the
Second aim, among elderly Medicare beneficiaries diagnosed with incident breast, colorectal,
prostate, ovarian, uterine cancer, or Non-Hodgkin’s lymphoma in 2014 (N = 36,447), only one in
five eligible adults received an AWV in 2015. Overall, 16.5% of the cohort had an AWV in
2015. The AWV rate in the non-cancer cohort was 16.7%. AWV rates were high among
individuals with breast (20%) and prostate (19%) cancer, followed by uterine cancer (16%) and
NHL (13%). The lowest rates were among individuals with ovarian cancer (7.5%). In the third
aim, among elderly Medicare beneficiaries diagnosed with incident breast, colorectal, prostate
and non-Hodgkin’s lymphoma (N = 27,067), Individuals who received one or more low-value
procedure had significantly higher mean out-of-pocket expenditure ($8,726±$7,214) vs.
($6,802±$6,102) compared to those who did not have low-value care in the follow-up period.
On average, patients who received a low-value procedure experienced between $1,000 and
$2,000 higher out-of-pocket expenditure attributable to low-value care. The machine learning

models identified low-value care, fragmentation of care, and a higher number of pre-existing
chronic conditions to be the most important factors driving excess out-of-pocket expenditure.
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CHAPTER 1
1. Introduction
1.1 Background and Significance
Definition and Prevalence of low-value care
In the United States (US), 25% ($955 billion) of healthcare spending is considered
wasteful because it is spent reimbursing low-value care.1,2 Low-value care is defined as the
utilization of healthcare services, medical tests, and procedures that have unclear or no clinical
benefit to patients but still exposes them to risk.3,4 World-wide, low-value care imposes high
clinical, humanistic, and economic burden for patients, payers, governments, stakeholders, and
the society5. Consequently, several campaigns (example: Choosing Wisely campaign by the
American Board of Internal Medicine Foundation,6 the United Kingdom’s National Institute for
Care and Health Excellence (NICE) and the Australian Medical Benefits Schedule (MBS)7 have
compiled a list of low-value care services that should be discouraged.
Low-value care includes both overuse and overtreatment – defined as inappropriate care
or care that may be inappropriate only under certain circumstances.8 The Institute of Medicine
(IOM) recognized the problem of low-value care as early as 19989 in its framework of six
domains of healthcare quality.10 The (IOM) concluded in their 2010 report that reducing lowvalue services is critical to lowering costs and improving outcomes in the US.11 One key
recommendation was a shift from the prevailing fee-for-service structures towards value-based
reimbursement that focuses on value and quality of care delivered.12
Low-value care is a major problem globally,5 and prevalence rates of low-value care
range from 30% in the United States (US),13 20% in Australia,14 33% in Germany,15 30% in
Canada,16 18-25% in France,17 and nearly 89% in other countries.5 In Virginia, providers
ordered 5.4 million of 44 measured low-value care services in 2014.18 A survey of physicians in
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the US, reported that a majority of the physicians believed that up to 20% of medical care in the
US is unnecessary.13
Economic Burden of Low-value Care
The Economic burden associated with low-value care is very substantial. It is estimated
that the US wasted about $765 billion in 2010 on low-value care, administration, and fraud.2,12 It
is also reported that although many low-value services have low cost (< $538 per service), the
frequency and volume of the low-cost, low-value services contributed the most to the
unnecessary medical spending.18 Therefore, many leading policy groups, including the IOM,
have concluded that reducing low-value services is critical to lowering costs and improving
outcomes in the US.11
Factors associated with low-value care
Published literature suggests that payment structures, specifically fee-for-service,19
government policies,11 physician characteristics,20 geographic factors,21 and patient-level factors
like race and gender,22 can influence low-value care. Existing payment models such as the feefor-service payment structure contribute to low-value care by incentivizing quantity rather than
the quality of care and de-emphasizes preventive care and care coordination among providers.
Alternative payment structures like the value-based insurance design (VBID), which focuses on
the evidence-based value of specific services, have been proposed.11 Physician characteristics
such as physician specialty, physician ownership of imaging equipment, and the clinician's prior
imaging patterns were reported to be independent predictors of low-value back pain and neck
pain imaging.20
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Cancer and Low-value Care:
However, the relationship between specific chronic conditions such as cancer to lowvalue care is unknown. Understanding the relationship between cancer and low-value care is
important for several reasons because cancer is one of the top five conditions that contribute
most to mortality, morbidity, and cost burden in the US. 23,24 Furthermore, individuals with
cancer may be at high risk for receiving low-value care because of competing demands of other
chronic conditions,25 survival prognosis,26,27 and the over-cautious use of tests and therapies to
ease the patient’s anxiety.28
Previous studies have shown that cancer care is associated with high rates of low-value
care and waste of resources.21,29–31 For example, Neuner and colleagues found that among
women with breast cancer, 13% received a surgical biopsy without attempted needle biopsy,
27% received axillary lymph node dissection without attempted sentinel lymph node needle
biopsy and 41% received two or more follow-up mammograms within 12 to 24 months postincident surgery – all core low-value services identified by the choosing wisely campaign.
Another systematic review of European studies that reported low-value care in cancer found
rates of low-value care between 4% and 68% for procedures and treatments such as Trastuzumab
in non-HER2-positive metastatic breast cancer patients without previous treatment with
anthracyclines, or radical mastectomy in cancer < 3cm, or inappropriate off-label use of
anticancer drugs in various cancers.29 Lipitz-Snyderman et al. analyzed low-value service
utilization using SEER-Medicare data for patients > 65 years diagnosed with breast and prostate
cancer. The prevalence of low-value care ranged from 14% for low-value imaging procedures in
breast cancer to 41% for low-value imaging in early prostate cancer.32
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Non-cancer low-value care in Cancer Survivors
While the studies mentioned above assessed cancer-related low-value services, only a
handful of studies have evaluated non-cancer low-value services in patients with cancer. For
example, 33% of patients with head and neck cancer who underwent surgery received low-value
care measured as persistent postoperative opioid use.33 Schleicher et al, found significant
medication-specific low-value care in cancer patients - specifically for supportive medications
e.g. overuse of serotonin receptor antagonist antiemetic drugs in patients receiving
chemotherapeutic agents with a lower risk for causing nausea.34 Low-value cancer and noncancer-related emergency service use were common among end-stage cancer patients.35 To date,
no study has examined the risk of low-value non-cancer care among patients with cancer. There
is a critical need to assess the prevalence of low-value non-cancer care in patients diagnosed with
cancer and risk factors associated with the receipt of low-value care.
High-Value Care and its importance
While reducing low-value care is important, it needs to be framed within the context of
high-value care. High-value care is care with proven value and clinical benefit with no
significant trade-offs. High-value services typically include services like 1.) community-based
prevention services, 2.) primary and secondary level clinically-based prevention services (for
example, USPTF recommended Annual Wellness Visits), and 3.) tertiary prevention strategies to
slow the progression or reduce the disability caused by a disease.36 Such services, when
implemented, have the potential to save the healthcare system about $55 billion annually.36
However, research shows that Americans receive less than 60% of these recommended services.
Borsky et al. found that less than 10% of adults over 35 years of age had received all high
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priority recommended preventive care.37 Disparities in the rates of use for these high-value care
have also been documented.38
High-Value Care – Medicare reimbursed Annual Wellness Visits:
One of these principally underutilized preventive services is Medicare’s Annual Wellness
Visit introduced in 2011 as part of the Affordable Care Act to enhance coverage of preventive
health care services for older adults.39 The AWV was designed to provide the clinician an
opportunity to disengage from the disease-focused care usually given for routine office visits and
focus on in-depth discussions about the overall health care plan, including preventive care,
disease screening, and coordination of care.40 The annual wellness visit includes a
comprehensive list of recommended preventive services, including health risk assessments,
functional ability evaluation, screenings for depression and cognitive impairment, cancer
screening, and evaluation of chronic conditions.40 With the AWV, all Medicare beneficiaries are
afforded similar access to preventive care visits at no cost, and this is expected to reduce the need
for emergency medical care and overall healthcare resource utilization.
Prevalence of High-Value Care - Annual Wellness Visits
Previous studies on the impact of AWV found moderate improvements in outcomes like
the use of evidence-based vaccinations, screenings, referrals, and healthcare utilization.41–44
However, despite its potential incentives, the AWV has not been widely adopted. Previous
studies have reported significant disparities in rates of adoption and utilization of the AWV
among different populations;45 Non-Hispanic whites, women, and fee-for-service enrollees were
more likely to use the AWV.45 Non-Hispanic whites had 45% and 88% percent higher utilization
rates for AWV compared to African Americans and Hispanics respectively.43 However, no
studies have examined the rates and predictors of AWV among cancer patients or cancer
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survivors. Such studies are essential because identifying risk factors to the adoption of
recommended “high-value” preventive care can help minimize the utilization of low-value care,
reduce the need for emergency medical care, and improve health outcomes.
Cancer and High-Value Care – Annual Wellness Visits
Older adults with cancer and multiple chronic conditions may be less likely to utilize
high-value recommended care like the AWV due to competing health demands.43 The competing
demands of cancer and concurrent chronic disease presents unique challenges for treatment
planning and care coordination.21 Older adults with multiple chronic conditions may be less
likely to make a separate AWV visit as they are already overwhelmed by frequent visits.40 Chung
et al. found that adults with increased numbers of chronic conditions had significantly lower
odds of having an AWV.40 Furthermore, older adults with cancer may be less likely to utilize the
AWV because of the life-threatening nature of the disease,46 provision of care by multiple
providers,47 lack of communication between primary care providers, oncologists, and other care
teams,48–50 the “disease-oriented” health system design,51 lack of robust clinical guidelines for
the management of multiple conditions,52,53 fragmentation of care,54,55 and lack of patientengagement.56 There is a critical need to assess the association of cancer and pre-existing chronic
conditions to annual wellness visits among older Medicare beneficiaries to help inform
interventions targeted at improving high-value preventive care utilization.
Significance of the Study
It is estimated that the US wasted about $765 billion on low-value care, administration,
and fraud in 2010.2,12 It was also reported that although many low-value services have low cost
(< $538 per service), the frequency and volume of the low-cost, low-value services contributed
the most to the unnecessary medical spending.18 Cancer care among older adults (≥ 65 years) is
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one of the biggest drivers of healthcare expenditure in the US and accounts for 40% of all
spending,23 and with the rapidly aging population, healthcare costs are expected to increase
further. It is estimated that social security and Medicare accounted for almost 40% of all federal
government spending in 2016.57
Reducing healthcare spending has become an urgent priority in the US, and many leading
policy groups, including the IOM, have concluded that reducing low-value services is critical to
lowering costs and improving outcomes in the US.11 To this end, real-world evidence is needed
to facilitate policy interventions targeted at reducing low-value care and resource waste.
Examining the economic burden to patients and their families will provide meaningful data for
policymakers and payers on the economic cost of low-value care in elderly Medicare
beneficiaries and help drive efforts to improve quality.
There has been an emerging trend to provide value-based rather than fee-for-service care,
which has some inefficiencies. Many agencies such as CMS and the Institute for Healthcare
Improvement have proposed approaches to optimize healthcare system performance. These new
approaches emphasize “triple aims” for a healthcare system that includes “improving the health
of populations, providing patient-centered value-based care at low per-capita healthcare costs”.58
Thus, reducing low-value care and associated healthcare spending is a priority for the
government and policymakers. As real-world evidence is key to finding possible ways to cut
resource waste in healthcare, this study examined the relationship of cancer to low-value care as
well as low-value care cost burden. We leveraged linked population-based cancer registries,
Medicare claims, and data on healthcare infrastructure, and provides meaningful information for
policymakers and payers on the economic cost of low-value cancer and non-cancer care in adults
> 65 years.
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1.2 Innovation
• This study represents a series of firsts.
•

This is the first real-world study to date to perform a comprehensive review of low-value
care among patients with cancer and multimorbidity across all settings and providers.

•

The study identifies novel risk factors of low-value care in patients with cancer and
multimorbidity by comparing receipt of low-value care across several types of cancers
and with a matched non-cancer cohort and includes data from diverse sources to identify
leading predictors.

•

This study is the first to utilize diverse data sources – including cancer registry data
(SEER), medical claims data (Medicare), area health resource files, census-level, and
county level ranking data, and clinical variables like cancer type and staging, to study the
association of cancer to low-value care.

•

This is the first study to focus on the receipt of low-value care in cancer, a significant
cause of mortality and healthcare utilization.

•

This is the first study to make use of machine learning approaches to identify the leading
predictors of low-value care.

•

This is the first study to employ model-agnostic interpretable machine learning tools to
“unpack” the black box of prediction.

Findings from the three studies in this dissertation can inform policy. This dissertation
identified the association of cancer and pre-existing chronic conditions with low-value service
use. Such information can help policymakers, payers, and other stakeholders to target specific
sub-populations of patients for information and developing interventions to reduce the likelihood
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of receiving low-value care. The leading predictors of low-value care among cancer patients we
identified in this study can inform which sub-populations to target for campaigns to reduce rates
of low-value care. Our findings can inform payers and policymakers in guiding payment
structures that focus on value-based care by providing up-to-date excess cost estimates of lowvalue care.
1.3 Specific Aims
Aim 1: Assess the association of incident cancer (breast, prostate, colorectal, and NonHodgkin’s cancer to low-value non-cancer care among older Medicare beneficiaries using
machine learning methods.
Hypothesis: Older fee-for-service Medicare beneficiaries with incident cancer will be more
likely to receive low-value non-cancer care compared to those without cancer.
Aim 2: Assess the association of incident cancer (breast, colorectal, prostate, ovarian,
uterine cancer, or Non-Hodgkin’s lymphoma) to annual wellness visit utilization among
older adults using machine learning methods.
Hypothesis: older fee-for-service Medicare beneficiaries with incident cancer will be less likely
to have annual wellness visits compared to those without cancer.
Aim 3: Examine the association of low-value care to economic burden (out-of-pocket
expenditure) of older cancer survivors (breast, prostate, colorectal, and Non-Hodgkin’s
lymphoma) using machine-learning methods.
Hypothesis: Low-value care and care fragmentation will be the leading predictors of out-ofpocket expenditure among older cancer survivors.
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1.4 Approach
Conceptual framework
Aim 1: The conceptual framework for aim 1 was adapted from the modified Donabedian’s
structure-process-outcome model.59 Briefly, this model posits that patient care outcomes are
influenced by the structure and process of care delivery (Fig 1.) Structure refers to the attributes
of the setting where care is delivered and may include facility variables, reimbursement
structure, and resource factors. Process refers to the techniques of care delivery that encompass
physician communication, fragmentation of care, and implementation of treatment plans.
Outcomes refer to the measured health effect of care in patients and could be a clinical outcome
variable, e.g., HbA1c reductions,60 or a quality measure, e.g., receipt of low-value care,61

Fig 1.1: Donabedian Structure Process Outcome Theoretical Framework
Context
Socio-demographic characteristics,
multimorbidity, lifestyle
Structure
Care facility characteristic,
Geographic location, Physician
training, Access, # of urgent care
centers per capita.

Processes
Fragmentation of care, Continuity
of care, Multidisciplinary care,
Preventive services,
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Quality of
care
Economic
burden

Aim 1.2. The conceptual framework for aim 2 was adapted from Anderson's behavioral
framework, 62,63 Briefly, Anderson's model posits that health care use and health outcomes are
influenced by a combination of predisposing, need, enabling, and external environment
factors.64,65 Predisposing factors are the individual-level factors that determine an individual’s
inclination to use health services. Enabling factors are the resources available to individuals that
enable them to access care. (Fig 2.)
Fig 1.2: Andersons Behavioral Framework
Predisposing factors
Demographics: age, and race/ethnicity
Enabling factors
Census tract socioeconomic factors (median
household income, % with college education)

Need factors

Dependent
Variable
Annual Wellness
Visit

Chronic physical conditions, mental
conditions, Cancer type, cancer stage
External environment factors
SEER region, area of residence (metro/nonmetro), county level % of psychologists and
community mental health centers

Aim 3. To estimate costs associated with low-value cancer and non-cancer care, we used the
WHO cost of illness framework adapted from rational consumer and constrained utilization
maximization principles. The theory assumes that healthcare utilization provides a level of utility
to the consumer and leads to healthcare expenditure. The model takes into consideration both
clinical and social determinants using a bottom-up approach to estimate expenditures and regards
expenditures as the outcome of the healthcare process. Social determinants include factors like
demographics, geography, social support, health behaviors, and socio-economic factors (Fig.3).
11

Fig 1.3: Adapted Cost of Illness Framework

Economic Burden
(out-of-pocket
Expenditure)

Type of Service
Inpatient
Low-value care
Nursing Home

1.5 Data Sources
Data for the study was derived from the Surveillance, Epidemiology, and End Results (SEER).
SEER Cancer: The SEER Program is an epidemiologic surveillance system consisting of
population-based tumor registries that collect data on all incident cases of cancer in persons
residing in 18 SEER areas. SEER cancer registry areas include (Atlanta, Connecticut, Detroit,
Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles
and San Jose-Monterey, Rural Georgia, Alaska Native, Greater California, Kentucky, Louisiana,
New Jersey, and Greater Georgia). SEER also collect information about patient’s demographic
characteristics, diagnosis date, cancer site, stage and grade of cancer, type of surgical treatment,
and radiation therapy provided within four months of diagnosis.66,67
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SEER-Medicare: SEER data have been linked to Medicare claims. Medicare data files consist
of claims from inpatient, outpatient, physician services, home health, durable medical equipment,
and prescription drug ﬁles.
SEER-Non-Cancer: To compare cancer and non-cancer cases, we used a random sample of
Medicare beneficiaries without cancer. The SEER non-cancer database consists of a 5% random
sample of Medicare beneficiaries living in SEER areas. The people who have been reported to
SEER with an incident cancer are removed from this 5% random sample. The demographic and
other Medicare enrollment data for non-cancer cases are identical to those of cancer cases and
can be linked with the cancer files using each beneficiary’s unique Medicare claim number.67
Area Health Resource File: The AHRF is a publicly available data file provided by the
Department of Health and Human Services; it includes county, state, and national files. The
AHRF provides more than 6,000 variables for each of the nation's counties. The AHRF contains
information such as health facilities, health professions, and socioeconomic and environmental
characteristics. The basic file contains geographic codes and descriptors that can be used to link
it to other files and aggregate counties into various geographic groupings. AHRF was linked to
SEER-Medicare files using the Federal Information Processing System (FIPS) county codes.
American Community Survey (ACS) Census Tract Files ACS 2014 to 2018 census tract and
census zip code files were linked to PEDSF files by geographic codes, i.e., state and county.68
These files provide information on the census tract median household income and education
level.
1.6 Analytic Approach
Rationale for the machine learning approach
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Statistical models are often used to derive inferences based on known assumptions. For
example, regression-based models explain the relationship between risk factors (independent
variables) and outcomes. However, these statistical models are often based on strict assumptions
about additivity, linearity, and the probability distribution of residuals. Violations of these
assumptions often render the model uninterpretable and inaccurate.69 Although ML methods
have been in use for the past 70 years, they have only recently started gaining prominence in the
field of medicine as an alternative to traditional statistical methods to overcome the challenges
posed by traditional methods. Typically, ML methods use resampling techniques to partition
original data into training, validation, and test datasets and compare prediction errors across
these datasets. Numerous ML algorithms have been tested for predictive accuracy using existing
statistical datasets and have been shown to yield lower error rates than standard statistical
methods.69 Historically, one of the most widely used ML algorithms has been the Random Forest
(RF). The RF is a tree-based algorithm that offers a flexible, adaptive, and assumption-free
modeling tool for predictions. The RF model is a flexible alternative to logistic regression and
has been used to identify important predictors.69 We will implement standard ML algorithms to
identify the leading predictors of low-value care among patients with cancer and multimorbidity.
Multiple decision trees will be grown by randomly varying the predictors using bootstrap
samples of the data with replacement. Prediction errors will be estimated using the out-of-bag
(OOB) sample. We will also use Integrated Brier scores over time to assess prediction accuracy;
lower values of IBS indicate better prediction. Conditional probabilities and risk in clinical
practice where the relationships between a patient’s clinical characteristics and the outcome are
more likely to be complex. These challenges often limit the choice of analytical methods, and
ratios (with 95% confidence intervals) will also be derived as indicated above. All our RF
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models will be built using training data and evaluated using testing data to avoid model
overfitting and increase generalizability; the dataset will be randomly split- 70% training sample,
which will be internally validated and 30% test sample (OOB sample). OOB samples will be
used to estimate the accuracy of RF models.
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CHAPTER 2
Association of Incident Cancer with Low-Value Care among Elderly Medicare
Beneficiaries using Machine Learning Models
2.1 Abstract
Objective: To evaluate the association of incident breast, prostate, colorectal, and NonHodgkin’s cancer to low-value non-cancer care among older US adults enrolled in Medicare
using machine learning methods.
Methods:
We used a retrospective cohort study design with one-year baseline and one-year follow-up
periods.
We identified two cohorts of cancer and non-cancer patients. The cancer cohort consisted of
older adults (age > 65 years) with incident breast, prostate, and colorectal cancer or NonHodgkin’s lymphoma (NHL) diagnosed between January 2005 and December 2015. The noncancer cohort was derived from the Medicare 5% non-cancer random sample. We identified
relevant low-value services using ICD9/ICD10 and CPT/HCPCS codes from the linked health
claims. We used xgboost models to identify the leading predictors of low-value care and partial
dependence plots to examine the association of the different cancer types to low-value care.
Results:
The combined study cohorts included 529,452 individuals. Among the cancer cohort (N =
329,267) the majority were diagnosed with prostate (N = 133,633) and breast cancer (N =
106,555). Both Non-Hodgkin’s lymphoma and colorectal cancer made up less than 28% of the
total. Overall, the prevalence of low-value care was 24.3%. The prevalence of low-value care
differed significantly by cancer type; the highest rates were observed in patients diagnosed with
Non-Hodgkin lymphoma (34%) followed by colorectal cancer (29% ), while low-value care was
lowest among patients diagnosed with prostate cancer (22%). The association of cancer to low16

value care varied by cancer type; colorectal cancer and NHL were positively associated with
low-value care, but breast and prostate cancers were negatively associated with low-value care.
Conclusion:
One in four older fee-for-service Medicare beneficiaries received low-value care. The
association of cancer to low-value care varied by cancer type. The leading patient-level
predictors were fragmentation of care, the number of physical health conditions, and age; the top
community-level predictors were market characteristics, healthcare utilization, and social
determinants of health, suggesting that a multipronged approach that targets patient and systemlevel factors are needed to reduce the risk of low-value care among older adults.
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2.2 Introduction:
Low-value care is highly prevalent worldwide and imposes excessive clinical,28
humanistic,1 and economic burden.2 Low-value care is defined as the utilization of healthcare
services, medical tests, and procedures that have unclear or no clinical benefit to patients but still
exposes them to risk.3,4 Previous studies have reported prevalence rates of low-value care
between 5% to 45% in the United States.32,33,70–72 In the state of Virginia, providers ordered 5.4
million of 44 measured low-value care services in 2014.18 A survey of physicians in the US
reported that a majority of the physicians believed that up to 20% of medical care in the US is
unnecessary.13 Consequently, campaigns, for example Choosing Wisely campaign by the
American Board of Internal Medicine Foundation6 have compiled a list of low-value care
services that should be discouraged.
Published literature suggests that many factors influence low-value care. These include
payment structures, specifically, fee-for-service,19 government policies,11 physician
characteristics,20 geographic factors,21and patient-level factors such as race/ethnicity and
gender.22 However, the association of specific chronic conditions (for example, cancer) to lowvalue care is unknown. An evaluation of low-value care and its burden among patients with
cancer is important because cancer is one of the top five conditions contributing most to
mortality, morbidity, and cost burden in the US.23,24 Individuals with cancer may be at high risk
for receiving low-value care because of competing demands,25 improved survival,26,27 and the
over-cautious use of tests and therapies to ease the patient’s anxiety.28 Furthermore, older
individuals with cancer may be at high risk for low-value care because many individuals with
incident cancer have multiple pre-existing chronic conditions, which may further increase the
risk for low-value care because of “disease-oriented” health system design,51 lack of robust
clinical guidelines for the management of multiple conditions,52,53 and fragmentation of care.54,55
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Therefore, this study aims to evaluate the association of incident breast, prostate, colorectal, and
Non-Hodgkin’s cancer to low-value non-cancer care among older US adults who are enrolled in
Medicare using machine learning methods. We focus on older Medicare beneficiaries because
Medicare covers nearly 90% of all older adults in the US.73 We focus on these select cancers
because they are some of the most prevalent cancers in older adults.
2.3 Methods
Data source:
We leveraged data from multiple sources and linked the Surveillance, Epidemiology, and
End Results (SEER) data, Medicare claims (inpatient, outpatient, physician services, and home
health agency claims), Area Health Resources File (AHRF), census, and 5% non-cancer sample
from the SEER regions. The SEER Program is an epidemiologic surveillance system consisting
of population-based tumor registries that collect data on all incident cases of cancer in persons
residing in 18 SEER areas. SEER cancer registry areas include (Atlanta, Connecticut, Detroit,
Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles
and San Jose-Monterey, Rural Georgia, Alaska Native, Greater California, Kentucky, Louisiana,
New Jersey, and Greater Georgia). SEER also collect information about patient’s demographic
characteristics, cancer diagnosis date, cancer site, stage and grade of cancer, Medicare
enrollment, HMO participation, and other variables.66,67
Study Design:
We adopted a retrospective cohort study design with a one-year baseline and one-year
follow-up periods. The baseline period was anchored to the cancer diagnosis date for the cancer
cohort and pseudo-diagnosis date based on service dates for the non-cancer cohort. The 12month pre-diagnosis period was set as a baseline, and the 12-months after diagnosis were used as
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follow-up period. We assessed all independent variables (i.e., features) during the baseline period
and the follow-up period was used to measure low-value care (i.e., the target variable).
Study Cohorts:
Two cohorts (cancer and non-cancer) were identified. The cancer cohort consisted of
older adults (age > 65 years) with any of the following incident and primary cancer: breast,
prostate, and colorectal cancer or Non-Hodgkin’s lymphoma (NHL) between January 2005 and
December 2015. The non-cancer cohort consisted of older adults without any cancer derived
from the 5% Medicare sample files from the SEER region with service dates between 2005 and
2015.
We included adults (age ≥ 66 years) diagnosed with the following cancer types: breast, prostate,
colorectal cancer, and NHL between January 2005 and December 2015. These patients were
required to have only one primary cancer diagnosis, to be alive during the calendar year, and the
cancer was not diagnosed from an autopsy report or death certificate. We included fee-forservice beneficiaries with continuous Part A and B enrollment during the study period. We set
the age ≥ 66 years to capture Medicare-covered services 12-month before diagnosis as most
individuals qualify for Medicare enrollment at 65 years.
Measures
Dependent Variable: Low-value care:
We identified low-value care (or services) based on previously published methodology
by Schwartz et al. 74 and Colla et al. 75 representing some of the previously published Choosing
Wisely recommendations. Appendix A shows the list of low-value care included in this study.
For each indicator procedure, we identified individuals in whom the use of the procedure is
likely to be low-value care given that it is not clinically indicated. We used ICD9/ICD10 and
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CPT/HCPCS codes (Appendix A) to identify relevant procedures from the inpatient, outpatient,
physician, and home health agency files.
Key Feature:
Cancer versus No Cancer:
The key independent variable was the presence of the following primary cancers: breast,
prostate, colorectal cancer, and NHL between Jan 2005 and December 2015. Individuals without
cancer were identified from the 5% random sample of Medicare beneficiaries living in the SEER
regions.
Other Features:
The selection of features was guided by published literature, the conceptual framework
for quality of healthcare proposed by Donabedian, 59 and feature selection and dimensionality
reduction algorithms. Briefly, Donabedian’s framework posits that outcomes of patient care are
influenced by the context, structure, and process of care delivery.59 Context factors included
patient-level factors (age at index date (66-69, 70-74, 75-79, or >=80 years); sex -male or
female; race -Non-Hispanic White, Non-Hispanic African American, Latinx, or others), health
status (chronic conditions including asthma, arthritis, chronic obstructive pulmonary disease,
diabetes, coronary artery disease, congestive heart failure, hypertension, hyperlipidemia, chronic
kidney disease; mental health conditions included dementia, bipolar disorder, depression, or
anxiety), social determinants (zip-code level income and education, county-level Medicare and
Medicaid dual eligibility), geographic region (Northeast, South, North-Central, or West;
rural/urban -metro, urban, or rural). Structure factors included county-level healthcare structure
(health professional shortage area for PCPs -whole county, part of county, or no shortage),
county-level healthcare quality(30-day readmission rates, emergency department visits per 1000
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population, 3-year malignant neoplasm mortality rates) and market characteristics (Medicare
advantage penetration). Process factors included patient-level fragmentation of care, preventive
services use and healthcare utilization. Fragmentation of care was measured using a claimsbased fragmentation of care index (FCI).76 FCI measures the dispersion of care across multiple
providers and specialties; preventive service use consisted of receiving influenza vaccination,
and healthcare use was measured with ED and inpatient visits.
Analytical Approach:
Machine Learning Algorithm (ML)
Statistical regression-based models are often used to examine the relationship between
risk factors (independent variables) and outcomes. However, these statistical models are often
based on strict assumptions about additivity, linearity, and the probability distribution of
residuals. Violations of these assumptions often render the model uninterpretable and inaccurate.
Therefore, ML algorithms have emerged as an alternative to overcome some of these
disadvantages. Many ML methods make use of decision trees because tree-based algorithms
offer flexibility and adaptiveness and do not rely on statistical probability distributions for
predictions.77 ML algorithms routinely use resampling techniques to partition original data into
training, validation, and test datasets. Models are built and tuned with training datasets to
minimize prediction error. However, the final prediction is often based on the “unseen” test
datasets.
There are many decision-tree-based ML algorithms available. We selected the xgboost
algorithm - a more efficient modification of the gradient boosted decision trees. Boosting is a
complex ensemble machine learning technique that corrects for errors made by previous trees by
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predicting the residuals of previous trees and performing additive optimization for new trees
using these residuals.78
We implemented the xgboost algorithm using R software.79 We partitioned our data into training
and test data by randomly splitting the data into a 70% training sample and a 30% test sample.
The training data was used to maximize prediction by training and tuning the models with
hyperparameters. The test dataset was used to evaluate model performance and estimate
prediction errors.
ML algorithms perform best when the positive and negative classes of the target variable
are equally split. For target variables with imbalanced distributions, balancing approaches need
to be applied. As our target variable (i.e., low-value care) was below 25%, the negative class
was significantly overrepresented in our dataset. Therefore, we used several balancing
techniques. We oversampled the minority class because of this class imbalance using Random
Over-Sampling Examples (ROSE) package in R. We used the mean imputation method to deal
with missing data for features (zip-code level median income, education, Medicare and Medicaid
dual eligibility) with less than 50% missing values. Features with more than 50% missing values
were excluded from the analysis. We used one-hot encoding for categorical variables with more
than two levels.
We conducted stratified machine learning predictions by cancer type because the cancer types
included in this study differed significantly with respect to the patient population affected, their
prognosis and survival, as well as treatment guidelines and management.
Evaluating Prediction:
Model performance was evaluated using test datasets with AUC, accuracy, recall, and specificity
parameters. The recall is a measure of the sensitivity of a model and is calculated as (True
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positives / (True positive + False negative)), while specificity is the negative predictive value and
calculated as (True negatives/(True negatives + False Positives)). Accuracy is the power of the
model to correctly classify both positive and negative classes.
Predictors of low-value care:
We identified leading predictors of low-value care with permutation feature importance.
The feature importance is derived by randomly permuting the column values of a feature and
then passing the sample back through the model and recompute the accuracy.80 We plotted the
global importance charts using the mean decrease in accuracy importance to identify the top-10
predictors of low-value care.
Association of cancer to low-value care
A major challenge of machine learning is the focus on prediction accuracy without
meaningful explanations of the predictions. Explaining these predictions by individual predictors
requires interpretable machine learning approaches; Several model-agnostic interpretable
machine learning approaches open these “black-box” models at the level of individual
predictors.81 We used the Shapely Additive explanations (SHAP) explanation technique
developed by Lundberg et al.82 because it has been proven to provide local accuracy and
consistency across all types of models.81,83 SHAP values originated from game theory,84 and
measure the importance of a feature by comparing the model prediction when the feature is
present and when it is removed from the model.
We present the association of cancer to low-value care using SHAP dependence plots.
These dependence plots show the marginal effect each feature has on the predicted outcome of
our model.78 It shows the change in SHAP values across all ranges of values for each feature.
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This helps explain whether the relationship between the target and a feature is linear or more
complex.
2.4 Results
The characteristics of cancer and non-cancer cohorts are summarized in Table 1. Among
the cancer cohort (N = 329,267) the majority were diagnosed with prostate (N = 133,633) and
breast cancer (N = 106,555). Both Non-Hodgkin’s lymphoma and colorectal cancer made up less
than 28% of the cancer cohort. The non-cancer cohort included 200,158 Medicare enrollees. The
majority of the population were female (52%), mostly white (83%), lived in metro areas (84%),
and had three or more pre-existing chronic conditions (56%). The most common chronic
conditions were hypertension (79%), hyperlipidemia (65%), and arthritis (27%). The mean age at
cancer diagnosis was (77 ± 6.99) and the mean fragmentation of care index was (0.61 ± 0.13).
Overall, the prevalence of low-value care was 24.3%.
The most common low-value care procedures identified were screening for carotid artery
stenosis in asymptomatic adult patients (10%), stress echocardiography for detection of
CAD/risk assessment in symptomatic or ischemic equivalent acute chest pain (4.2%), and lowvalue traction for low back pain (5%). (Table 1). The prevalence of low-value care differed
significantly by cancer type; the highest rates were observed in patients diagnosed with NonHodgkin lymphoma (34%) followed by colorectal cancer (29% ), while low-value care was
lowest among patients diagnosed with prostate cancer (22%).
Model Performance
Table 2 shows the model performance metrics (recall, accuracy, specificity, and AUC)
for the final tuned xgboost models. The colorectal cancer model had (88%) recall, (93%)
specificity, (91%) accuracy, and (87%) AUC. We compared the model performance metrics
between machine learning and traditional logistic regression. The xgboost models outperformed
25

logistic regression across all cancers with respect to model accuracy, sensitivity, specificity, and
AUC. For example, for colorectal cancer, the logistic regression model had (61%) recall, (66%)
specificity, (65%) accuracy, and (68%) AUC.
Association of Cancer to Low-value care
The SHAP dependence plots showing the association of type of cancer to low-value care
are presented in Fig 1. Dependence plots show the marginal effect of a feature on the predicted
outcome. Each point on the plot represents a row of the data. The x-axis indicates cancer [1] vs
non-cancer [0] categories. The vertical axis shows the effect of that feature value on the
probability of low-value care. The vertical spread shows that the association of cancer to lowvalue care varied widely. For example, in the NHL model, cancer was associated with a higher
likelihood of low-value care with SHAP values between 0 to 10%. This wide dispersion of
SHAP values is indicative of strong feature interactions. These figures indicate that patients with
breast or prostate cancer were less likely to have a prediction of positive class, and those with
colorectal cancer or NHL were more likely to have a prediction of the positive class.
Leading Predictors of Low-value care
Table 3 provides the ranking of feature importance for all cancer types. Across all the
cancers studied, the individual-level process of care factors (FCI), contextual factors (age,
number of chronic physical conditions, and zip-code level social determinants of health) were the
top five predictors of low-value care, with the highest mean contributions to the overall
predictions. The other consistent predictors comprised the county-level number of ED visits per
1000 beneficiaries, rate of Medicare advantage penetration, Medicare beneficiary hospital
readmission rate, preventable hospital stay rate, and dual eligibility for Medicare and Medicaid.
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Some factors were not consistent across cancer types. For example, Dual eligibility for Medicare
and Medicaid predicted low-value care in NHL and not other cancers.
We present the local and global explanations for each model using SHAP importance
plots in Fig 2. The features are ordered in descending order of importance based on the mean
SHAP value. Each point on the plot represents an observation in the data; the x-axis value
indicates the effect of the feature on the final prediction; negative values mean a negative
association with low-value care while positive values positively correlate with low-value care
and increase the prediction. The color gradient represents the value for that feature, with yellow
corresponding to lower values of the feature and purple corresponding to higher values. The
mean SHAP value for that feature is presented on the left next to the feature label. For example,
in the prostate cancer model, higher values of FCI were associated with low-value care, and its
contribution to the overall prediction of low-value care increases up to 45% for extremely high
values of this feature. For the number of chronic physical conditions, higher values are positively
associated with low-value care, and the contribution increases to over 50% for extremely high
values of this feature.
The interactions among the top features in our models are presented in Figures 3 - 6. The
vertical spread indicates another interaction driving the wide variation in SHAP values for the
same feature value. The feature interactions differed significantly by cancer type. For example,
in the prostate cancer model (Fig 6), the interaction between age and cancer and their effect on
the prediction is complex. For individuals between 66 – 79 years of age, cancer was negatively
associated with low-value care and decreased the likelihood of low-value care by about 10%.
However, for individuals over 80 years of age, having prostate cancer was positively associated
with low-value care and increased the likelihood of low-value care between 10% and 25%. For
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the colorectal cancer model, the strongest interactions were observed between cancer and FCI,
and between age and cancer. Some other noteworthy interaction pairs are the number of physical
health conditions and cancer. For the Prostate cancer model, the significant interaction pairs were
fragmentation of care index and cancer, FCI, and the number of physical health conditions and
cancer, age, and cancer.
2.5 Discussion
In this first nationwide study of leading predictors of low-value care with machine
algorithms, we observed that one in four adults (24%) received at least one of 20 low-value care
services. In our study, the prevalence rates of low-value care differed by cancer type, with the
highest rates in patients diagnosed with incident NHL (33%) followed by colorectal cancer
(29%), breast cancer (24%), and prostate cancer (22%). These findings are consistent with rates
between 5% - 45% observed in previously published studies.32,33,70–72 For example, the
prevalence rate of low-value care in breast cancer is consistent with the rate reported by LipitzSnyderman et al. using SEER-Medicare data.32 This study’s finding of increased rates of lowvalue care in some cancers is consistent with previous literature, showing that patients with
cancer have higher risks of receiving low-value care.32,33 A systematic review by Schleicher et al.
reported very high rates of cancer-related as well as supportive medication-related low-value
care.34 It has to be noted these studies are not strictly comparable because of variations in the
definitions of low-value care. For example, our study included 20 services, while LipitzSnyderman et al. included only five services.
The most used low-value care services were population-based screening for detection of
carotid artery disease (10%), low-value MRI for low back pain (9.8%), traction for low back pain
(5%), and repeated dual-energy x-ray absorptiometry (9%). Many studies report a high
prevalence of inappropriate imaging studies for low-back pain.19,71,85 Our findings suggest that
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interventions targeting these procedures may help reduce the risk of low-value care among older
Medicare beneficiaries with and without cancer.
The association of cancer to low-value care differed by cancer type. Older adults
diagnosed with incident NHL and colorectal cancers were more likely to receive low-value care,
and those diagnosed with incident breast and prostate cancers were less likely to receive lowvalue care. These differences in the relationship between cancer and low-value care may be due
to variations in the patient populations, survival prognosis, clinical priorities, and approach to
managing co-occurring chronic conditions. For example, prostate and breast cancers have 90%
and 95% 5-year survival, respectively. However, the 5-year survival for colorectal cancer and
NHL is lower (~75%).86 We observed a higher number of chronic physical conditions in those
with colorectal cancer and NHL, suggesting that competing demands and approaches to
managing chronic conditions may trigger more procedures resulting in higher rates of low-value
care. Providers may feel pressured to manage cancer as well as physical conditions and may
order more tests rather than having patient discussions that may be emotionally difficult for
patients and their families.87
The leading patient-level predictors of low-value care identified by the xgboost model
were FCI, age, and the number of physical health conditions. The relationship of FCI to lowvalue care was non-linear. There was no relationship between FCI and low-value care for FCI
0.2 and 0.4. These findings suggest that the relationship of FCI to low-value care is non-linear
and complex. While this study did not explore the reasons for fragmented care, we speculate that
for some individuals, the FCI variable may reflect appropriate need, and seeing multiple
providers may lead to a lower likelihood of low-value care in these individuals; for others, it may
reflect fragmented care and such care may lead to a higher likelihood of low-value care. There is
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some evidence that some patients with complex healthcare needs (example: multiple cooccurring conditions) may benefit from seeing multiple specialists,88–90 and this may account for
the lower probability of receiving low-value care at some levels of FCI. Future studies need to
unpack the benefits of seeking care from multiple providers versus care fragmentation versus
within fee-for-service systems.
Consistent with published literature, we found age to be a leading predictor of low-value
care.22,71 Studies report that older patients are more likely to be referred for unnecessary tests
compared to younger patients. 91 In our study, the ML algorithms not only confirmed this
relationship but also highlighted the complexity in the association of age to low-value care and
its variation across cancer types. As seen in the interaction plots, there was considerable
variation in this complex relationship by cancer type. For example, individuals aged 80 or older
with incident prostate cancer were more likely to receive low-value care. However, individuals
aged 85 or older with incident NHL were less likely to receive low-value care. Our findings
suggest that future research and demand-side interventions with patient-focus,92–94 and providerand consumer-led efforts may need to target “older patients”. Provider-led interventions that
have engaged patients and families in defining, identifying, and communicating about low-value
care and engaged the patient-physician dyad in shared decision making have been successful.95
Informational campaigns that target or discourage specific low-value services and promote
evidence-based high-value care, when incorporated into clinical practice have been proven to
change patients' perceptions and behavior regarding the value of specific care and helped reduce
low-value care in this population.96–98 Supply-side interventions targeting providers such as
clinical decision support and clinician education have been effective,99–102 but others like risksharing, pay-for-performance, and provider report cards need to be further investigated.103
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A noteworthy finding is the association of zip-code level social determinants to low-value
care. The relationship between education, median income, and low-value care was complex,
above the median income of $100,000, increasing values increased the likelihood of low-value
care while the relationship was inverse for values of income below $50,000. This complex
relationship may be explained by the effects and interaction of patient socioeconomic
characteristics and access to healthcare on health service utilization.104–108 This finding
emphasizes the importance of integrating social determinants of health in interventions to reduce
the prevalence of low-value care in cancer and non-cancer patients. 109–111
We also observed that market characteristic was consistently associated with low-value
care. Specifically, higher rates of Medicare advantage penetration were associated with lower
probabilities of low-value care. It has been documented that Medicare beneficiaries in managed
care are less likely to receive low-value care compared to their fee-for-service counterparts.3
Plausible explanations for these area-level effects may be related to the so-called “spillover
effects.”112 An increase in the proportion of managed care plans in an area can affect physician
practice patterns both for managed care and fee-for-service patients; the ensuing spillover of
managed care policies eventually benefits all patients in their care.113 Previous research suggests
that this “spillover” may be substantial when managed care patients comprise a significant
proportion of physicians’ or hospitals’ practice.113,114
In this study, a higher number of ED visits per 1000 beneficiaries was associated with
higher probabilities of low-value care for many cancer types. There is some evidence that
emergency departments may provide low-value care services at a high rate. It has been reported
that imaging studies are overused in emergency departments85,115–117 Although ED visits may be
influenced by the health system and patient-level factors, a road map to reducing low-value care
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provided through benefit-sharing,118 and other recommendations outlined in the 2008 American
College of Emergency Physicians report may help in reducing low-value care in EDs.119,120
In this first study using ML algorithms to identify predictors of low-value care and the
association of cancer to low-value care, we found that the ML algorithms were superior to the
traditional logistic regression. The Accuracy, ROC, sensitivity, and specificity were all
significantly better for the xgboost models compared to the logistic regression models for all four
cancers. The ML algorithms also highlighted the complex and non-linear relationships of
predictors to low-value care, suggesting that a “one-size fits all” approach to reducing low-value
care may not be an ideal strategy in reducing the risk of low-value care.
2.6 Conclusion
One in four older fee-for-service Medicare beneficiaries received low-value care. The
association of cancer to low-value care varied by cancer type. The leading patient-level
predictors of low-value care included fragmentation of care, the number of chronic conditions,
and age. The leading community-level predictors were market characteristics, healthcare
utilization, and social determinants of health, suggesting that a multipronged approach that
targets patient and system-level factors is needed to reduce the risk of low-value care among
older adults.
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TABLES AND FIGURES
Table 2.1: Description of Eligible Adults diagnosed with Breast, Colorectal, Prostate Cancers and NonHodgkin’s Lymphoma and Non-Cancer Control Group
SEER-Medicare, 2005 – 2015
Characteristics
N
%
List of Low-Value Care Procedures
N
%
Cancer status
Imaging for adnexal cyst
Cancer
329267 62.2
Low-Value care
151
0.0
Non-cancer
200158 37.8
No Low- Value care
529274 100.0
Cancer Type
Arthroscopic surgery for knee osteoarthritis
Breast Cancer
106555 20.1
Low-Value Care
148
0.0
Colorectal Cancer
65519
12.4
No Low- Value care
529277 100.0
Prostate Cancer
133622 25.2
Low-value Digoxin monitoring
Non-Hodgkin’s Lymphoma
23571
4.5
Low-Value Care
9956
1.9
Non-cancer
200158 37.8
No Low- Value care
519615 98.1
Gender
Imaging of carotid arteries for simple syncope
Female
276003 52.1
Low-Value Care
21344
4.0
Male
253422 47.9
No Low- Value care
508084 96.0
Age group
Hypercoagulability testing for clotting disorders
66-69 years
144121 27.2
Low-Value Care
846
0.2
70-74 years
137992 26.1
No Low- Value care
528588 99.8
75-79 years
105206 19.9
Low-value immunoglobulin testing for allergy
≥80 years
142106 26.8
Low-Value Care
3994
0.8
Race
No Low- Value care
525456 99.3
White
438478 82.8
LVC filters to prevent PE
African American
45657
8.6
Low-Value Care
2306
0.4
Others
45290
8.6
No Low- Value care
527119 99.6
Region
Low-value laminectomy or spinal fusion
Northeast
103789 20.4
Low-Value Care
1794
0.3
South
126341 24.8
No Low- Value care
527632 99.7
North Central
58018
11.4
Fiberoptic laryngoscopy for uncomplicated
rhinosinusitis
West
220463 43.3
Low-Value Care
4314
0.8
Number of Physical Health Conditions
No Low- Value care
525111 99.2
None
62699
11.8
Low-value MRI for minor head injury
1-2
171907 32.5
Low-Value Care
330
0.0
3 or more
294819 55.7
No Low- Value care
529095 99.9
Preventive Flu Vaccination
Low-value Imaging for uncomplicated headache
Yes
228737 43.2
Low-Value Care
1506
0.3
No
300688 56.8
No Low- Value care
527919 99.7
ED visit
Low-value screening for carotid artery stenosis
Yes
70773
13.3
Low-Value Care
53378
10.1
No
458652 86.6
No Low- Value care
476064 89.9
Depression
Serology for Helicobacter pylori
Depression
45437
8.6
Low-Value Care
5235
1.0
No depression
483988 91.4
No Low- Value care
524227 99.0
Rural/Urban residence
Stress echocardiography for detection of CAD
Metro
444649 84.0
Low-Value Care
22214
4.2
Urban
73560
13.9
No Low- Value care
507211 95.8
Rural
10180
1.9
T3 Testing for hypothyroidism
unknown
1003
0.2
Low-Value Care
10301
1.9
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Table 2.1: Description of Eligible Adults diagnosed with Breast, Colorectal, Prostate Cancers and NonHodgkin’s Lymphoma and Non-Cancer Control Group
SEER-Medicare, 2005 – 2015
Characteristics
N
%
List of Low-Value Care Procedures
N
%
Income
No Low- Value care
519186 98.1
$8,650 - $37,401
101095 19.1
Traction for low back pain
$37,404 - $49,340
99665
18.9
Low-Value Care
26587
5.0
$49,360 - $62,486
91261
17.2
No Low- Value care
503016 95.0
$62,487 - $84,239
87556
16.5
Population-based Vit-D Screening
$84,289 - $250,014
94948
18.0
Low-Value Care
3264
0.6
Preventive HbA1c Testing
No Low- Value care
526186 99.4
Preventive A1c testing
72547
13.7
No preventive A1c testing
456878 86.3
Preventive BMD Screen
Preventive BMD screen
18673
3.5
No preventive BMD screen
510752 96.5
Preventive Flu Shot
Preventive flu shot
228737 43.2
No preventive flu shot
300688 56.8
Preventive Lipid Testing
Preventive Lipid testing
128392 24.3
No preventive lipid testing
401033 75.7
Any Low-Value Care⃰
Yes
129203 24.4
No
400222 75.7
Radiation therapy
Radiation therapy
90151
27.4
No Radiation therapy
239116 72.6
Immunotherapy
Immunotherapy
12764
3.9
No Immunotherapy
316503 96.1
Chemotherapy
Chemotherapy
60604
18.4
No Chemotherapy
268663 81.6
Note: Based on 329,267 adults over 66-years, diagnosed with breast, prostate, colorectal cancers, and nonHodgkin’s lymphoma, living in any of the 18 SEER regions in the United States, and 200,158 non-cancer
controls randomly drawn from Medicare enrollees in SEER regions. All having continuous enrollment for 12
months baseline and 12months follow-up periods. Physical health conditions measured include Asthma, Arthritis,
Chronic obstructive pulmonary disease, Chronic Kidney disease, Cardiac arrhythmia, Congestive heart failure,
hypertension, hyperlipidemias, Diabetes, hepatitis, dementia.
⃰ Any low-value care includes all individuals that received any one of the measured low-value procedures in the
12 months follow-up period.
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Table 2.2: Model Performance for Logistic Regression and Machine Learning Models for Prostate, Breast,
Colorectal and Non-Hodgkin Lymphoma.
SEER-Medicare, 2005 – 2015
Model
Evaluation
Non-Hodgkin
Metrics
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lymphoma
Logistic
Logistic
Logistic
Logistic
Regression XGBoost Regression XGBoost Regression XGBoost Regression XGBoost
Accuracy
0.62
0.80
0.63
0.79
0.65
0.91
0.63
0.80
Sensitivity
0.60
0.85
0.65
0.84
0.61
0.88
0.67
0.86
Specificity
0.63
0.78
0.64
0.77
0.66
0.93
0.61
0.72
AUC
0.66
0.89
0.70
0.88
0.68
0.87
0.70
0.90
Note: Based on 329,267 adults over 66-years, diagnosed with breast, prostate, colorectal cancers, and nonHodgkin’s lymphoma, living in any of the 18 SEER regions in the United States, and 200,158 non-cancer
controls randomly drawn from Medicare enrollees in SEER regions. All having continuous enrollment for 12
months baseline and 12months follow-up periods.

Table 2.3: Global Feature Importance from XGBOOST Models for Prostate, Breast, Colorectal
and Non-Hodgkin Lymphoma.
SEER-Medicare, 2005 – 2015
Breast
Cancer
1
2
3
4
5
7
11
9

Colorectal
Cancer
1
2
3
4
x
6
9
10

NonHodgkin
Lymphoma
1
2
3
4
x
6
12
10

Prostate
Cancer
1
2
3
4
5
6
10
9

Feature
Care Fragmentation
Age
Number of Comorbidities
County-Level Poverty percentage
Cancer vs No cancer
Zip-Level Median Income
County level Medicare Advantage Penetration
County-Level Preventable Hospital Stay Rate
County-Level Medicare Beneficiary Hospital
readmission Rate
8
8
8
8
County-Level Emergency Department
Visit/1000 Beneficiaries
10
12
9
11
Medicare-Medicaid Dual Eligibility
12
11
11
12
Skilled Nursing Facilities Total Beds
15
13
15
13
Healthcare utilization (Inpatient)
13
14
13
x
Preventive Flu Vaccination
14
15
14
14
Note: Based on 329,267 adults over 66-years, diagnosed with breast, prostate, colorectal cancers, and
non-Hodgkin’s lymphoma, living in any of the 18 SEER regions in the United States, and 200,158 noncancer controls randomly drawn from Medicare enrollees in SEER regions. All having continuous
enrollment for 12 months baseline and 12months follow-up periods.

35

Fig 2.1: SHAP Dependence Plot for Association of Cancer to Low-value Care
Breast Cancer

Prostate Cancer

Non-Hodgkin’s Lymphoma

Colorectal Cancer

Note: smc_smnc_pop = Cancer status yes/no
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Fig 2.2 SHAP interaction plot for Breast Cancer

Note: Carefrag = Care Fragmentation. age_dx = Age at cancer diagnosis. Median_inc = Median Income. Phc_nbr =
Number of pre-existing chronic conditions. Brst = Breast cancer. clrl = Colorectal cancer. Prst = Prostate cancer.
smc_smnc_pop = Cancer status yes/no
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Fig 2.3 SHAP Interaction plots for Colorectal Cancer

Note: Carefrag = Care Fragmentation. age_dx = Age at cancer diagnosis. Median_inc = Median Income. Phc_nbr =
Number of pre-existing chronic conditions. Brst = Breast cancer. clrl = Colorectal cancer. Prst = Prostate cancer.
smc_smnc_pop = Cancer status yes/no
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Fig 2.4 SHAP Interaction Plot for Non-Hodgkin's Lymphoma

Note: Carefrag = Care Fragmentation. age_dx = Age at cancer diagnosis. Median_inc = Median Income. Phc_nbr =
Number of pre-existing chronic conditions. Brst = Breast cancer. clrl = Colorectal cancer. Prst = Prostate cancer.
smc_smnc_pop = Cancer status yes/no
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Fig 2.5 SHAP Interaction Plots for Prostate Cancer

Note: Carefrag = Care Fragmentation. age_dx = Age at cancer diagnosis. Median_inc = Median Income. Phc_nbr =
Number of pre-existing chronic conditions. Brst = Breast cancer. clrl = Colorectal cancer. Prst = Prostate cancer.
smc_smnc_pop = Cancer status yes/no
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Fig 2.6 : SHAP Summary Plot for Top 10 Predictors of Low-value Care
Colorectal Cancer

Breast Cancer

Prostate Cancer

Non-Hodgkin’s Lymphoma
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CHAPTER 3
Interpretable Machine Learning Applications: Cancer and Annual Wellness Visit among
Older Medicare Beneficiaries.
3.1 Abstract
The Annual Wellness Visit (AWV) is recommended by the US preventive services task force
because it effectively promotes preventive care, healthcare quality and reduces cost. Patients
with cancer may be less likely to utilize the annual wellness visits due to the competing demands
of cancer and concurrent chronic disease, presenting unique challenges for treatment planning
and care coordination. No studies have examined the rates and predictors of AWV among cancer
patients. We examined the association of cancer to AWV utilization among adults ≥ 66 years
diagnosed with incident breast, colorectal, prostate, ovarian, uterine cancer, or Non-Hodgkin’s
lymphoma.
Methods
We adopted a retrospective cohort study design with 12-month baseline and follow-up periods.
Two cohorts (cancer and non-cancer) of adults over 65 years were identified. The cancer cohort
consisted of individuals with any of the following incident and primary cancers; breast,
colorectal, prostate, ovarian, uterine cancer, or Non-Hodgkin’s lymphoma diagnosed between
January 2014 and December 2014. The non-cancer cohort was derived from the 5% non-cancer
Medicare sample. We identified individuals who received an annual wellness visit (Current
Procedural Terminology [CPT] codes in the follow-up year after cancer diagnosis. We Used
XGBoost models to identify the leading predictors of AWV.
Results
The combined cohort included 67,084 individuals. Overall, 16.5% used AWV during the followup period. The AWV rates in the non-cancer cohort was 16.7%; among the cancer cohort, the
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rates varied by cancer type; 20% for breast cancer, 19% for prostate, 16% for uterine, 13% for
NHL, and 7.5% for ovarian cancers. The association of cancer to AWV varied by cancer type;
There were no significant associations between breast and prostate cancer and AWV. Colorectal,
ovarian cancer, and NHL were associated with AWV
Conclusion
In this first population-based study evaluating AWV in cancer patients, approximately two out of
10 older fee-for-service Medicare beneficiaries had AWV in 2015. Our findings highlight low
uptake of AWV in older adults with and without cancer and, specifically, in minority
populations. The association of cancer to AWV varied by cancer type and AWV, suggesting that
interventions customized to specific types of cancers may be needed to improve the uptake of
AWV.

43

3.2 Introduction
The Annual Wellness Visit (AWV) is recommended by the US preventive services task
force (USPSTF)121 because of its effectiveness in improving preventive care,43 healthcare
quality,122 and reducing costs.122 Since 2010, Medicare has provided free coverage for AWV as
part of the Affordable Care Act (ACA).123 The AWV is a yearly appointment of patients with
their primary care provider to develop a personalized prevention plan.39 The AWV provides an
opportunity for the clinician to disengage from visit-specific, disease-focused care to look at the
overall care plan, including preventive care, disease screening, and coordination of care.39
During the AWV, patients receive health risk assessments, functional ability evaluation,
screenings for depression and cognitive impairment, cancer screening, and evaluation of chronic
conditions.39,123,124 This visit may also lead to referrals for additional screening or prevention
services and is expected to help reduce the need for emergency medical care and overall
healthcare resource utilization.125 AWVs have been found to improve vaccinations, cancer
screenings, referrals, and reduce healthcare costs.41–44
Since its inception, studies have shown a modest increase in AWV rates from 7% in 2011
to about 16% in 2014.45,126 Slightly higher rates of about 25.2% have been reported among
Medicare advantage enrollees.127 Significant disparities in AWV utilization have also been
documented;45 African Americans and Hispanics were less likely to use AWV compared to NonHispanic Whites. Another study found that males, younger adults, and individuals residing in
affluent areas were more likely to use AWV.128 However, no studies have examined the rates and
predictors of AWV among cancer patients or cancer survivors. Patients with cancer may be less
likely to utilize AWV due to competing health care visit patterns.43 The competing demands of
cancer and concurrent chronic disease presents unique challenges for treatment planning and care
coordination,21 because of the life-threatening nature of the disease,46 provision of care by
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multiple providers,47 and lack of communication between primary care providers, oncologists,
and other care teams.48–50 The objective of this study is to examine the association of cancer to
AWV utilization among adults ≥ 66 years diagnosed with incident breast, colorectal, prostate,
ovarian, uterine cancer, or Non-Hodgkin’s lymphoma using data from the Surveillance,
Epidemiology, and End Results (SEER) program.
3.3 Methods
Data source: We leveraged data from multiple linked data sources for this study, including the
Surveillance, Epidemiology, and End Results (SEER) Program, Medicare claims, county-level
area health resources, county-level health ranking, and census files. The SEER dataset is a
population-based tumor registry that collects data on all incident cases of cancer that occur in
persons residing in 18 SEER regions which include (Atlanta, Connecticut, Detroit, Hawaii, Iowa,
New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles and San JoseMonterey, Rural Georgia, Alaska Native, Greater California, Kentucky, Louisiana, New Jersey,
and Greater Georgia).66,67 To compare cancer and non-cancer cases, we used a random 5%
sample of Medicare beneficiaries without cancer living in SEER areas. The AHRF is a publicly
available data file provided by the Department of Health and Human Services and contains
county-level information such as health facilities, health professions, and socioeconomic and
environmental characteristics.
Study Design:
We adopted a retrospective cohort design for this study with 12-month baseline and
follow-up periods. We identified two cohorts (cancer and non-cancer) of adults over 65 years;
the cancer cohort consisted of individuals with any of the following incident and primary
cancers; breast, colorectal, prostate, ovarian, uterine cancer, or Non-Hodgkin’s lymphoma
diagnosed between January 2014 and December 2014 (cancer cohort). We selected the non45

cancer cohort from the 5% non-cancer Medicare sample with service dates between January
2014 and December 2014. The baseline period was anchored to the cancer diagnosis date for the
cancer cohort and pseudo-diagnosis date based on service dates for the non-cancer cohort. The
12-month pre-diagnosis period was set as the baseline, and we assessed all independent variables
during the baseline period; the follow-up period was used to measure AWV.
Inclusion criteria
We selected adults over 66 years diagnosed with primary and incident breast, colorectal,
prostate, ovarian, uterine cancer, or Non-Hodgkin’s lymphoma between January 2014 and
December 2014 who were alive during the calendar year and were not diagnosed from an
autopsy report or death certificate. We required beneficiaries to have continuous Part A and B
enrollment during the study period and not be enrolled in HMO plans during the study period
Measures:
Annual Wellness Visit: We identified individuals who received an annual wellness visit using
the relevant (Current Procedural Terminology [CPT] codes in the follow-up year after cancer
diagnosis.
Cancer versus No Cancer:
The key independent variable was grouped into six categories: 1) breast cancer, 2)
prostate cancer, 3) women with colorectal; 4) men with colorectal, 5) women with NHL; 6) men
with NHL, 7) women with no cancer and 8) men with no cancer.
Other independent variables:
We relied on published literature, Anderson's behavioral framework, 62,63 feature
selection, and dimensionality reduction algorithms to guide feature selection. Briefly, Anderson's
model posits that health care use and health outcomes are influenced by a combination of
predisposing, need, enabling, and external environment factors.64,65 Predisposing factors
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comprise patient-level factors including age at index date (66-69, 70-74, 75-79, or >=80 yrs.);
sex (male or female); race (Non-Hispanic White, Non-Hispanic African American, Hispanic, or
others); geographic region (Northeast, South, North-Central, or West); rural/urban residence
(metro, urban, or rural); Need factors include health status (chronic conditions including asthma,
arthritis, chronic obstructive pulmonary disease, diabetes, coronary artery disease, congestive
heart failure, hypertension, hyperlipidemia, chronic kidney disease; mental health conditions
included dementia, bipolar disorder, depression, or anxiety), enabling factors included social
determinants (zip-code level income and education, county-level Medicare and Medicaid dual
eligibility), access to care factors (patient-level fragmentation of care and preventive services
use). Fragmentation of care was measured using a claims-based fragmentation of care index
(FCI).76 External environment factors included community market dynamics (30-day
readmission rates, emergency department visits per 1000 population, 3-year malignant neoplasm
mortality rates, and Medicare advantage penetration.
Analyses plan:
Machine Learning (ML) model:
We used ML methods, specifically the XGBoost algorithm to identify the leading
predictors of AWV utilization. XGBoost is an ensemble technique that employs multiple
decision trees with gradient boosting. The advantage of using machine learning models over
conventional statistical methods is that ML models are flexible and adaptive and do not rely on
statistical distributional assumptions. XGBoost models employ an iterative process of additive
optimization using errors from previous trees by predicting the residuals of those previous trees
and improving subsequent trees using these residuals.
We evaluated the association of cancer to AWV by using variable importance plots and
interpretable machine learning methods. We used the global variable importance plot based on
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the mean decrease in accuracy to evaluate whether cancer was a leading predictor of AWVs. We
used the Shapely Additive (SHAP) explanations technique developed by Lundberg et al.82 to
analyze the direction of cancer association to AWV. We also used partial dependence plots to
visually represent the association of cancer to AWV. Each point on the dependence plot
represents a row of the data. The horizontal axis indicates cancer [1] vs. non-cancer [0]
categories, while the vertical axis shows the effect of that feature value on the probability of
AWV.
We used the caret and XGBoost packages in R to build and tune our models. We
partitioned our data into training and test data by randomly splitting the data into a 70% training
sample and a 30% test sample. The training data was used to train and tune the model while the
test sample was used to evaluate model performance. We used the mean imputation method to
deal with missing data for features with less than 50% missing values. Features with more than
50% missing values were excluded from the analysis. We used one-hot encoding for categorical
variables with more than 2 levels.
Evaluating model fit:
We evaluated the performance of our model using recall, AUC, accuracy, and specificity
parameters. The recall is a measure of the sensitivity of a model, while specificity is a measure of
the models’ negative predictive value. Accuracy refers to the models’ ability to correctly classify
both positive and negative outcome classes.
3.4 Results
The characteristics of cancer and non-cancer cohorts are summarized in (Table 1). The
cancer cohort comprised 36,447 individuals. The majority were diagnosed with prostate and
breast cancer (16% and 17%), respectively. NHL and colorectal cancer made up 6% and 11%,
respectively, and the lowest prevalence was for ovarian cancer (1.6%). Most of the population
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were female (57%), primarily white (81%), lived in metro areas (84%), and had three or more
pre-existing chronic conditions (55%). The most common chronic conditions were hypertension
(68%), hyperlipidemia (63%), and arthritis (27%). The mean age was (73 ± 7.69) and the mean
fragmentation of care index was (0.53 ± 0.21).
Overall, 16.5% of the cohort had an AWV during the follow-up period (Table 2). The AWV rate
in the non-cancer cohort was 16.7%. For some cancers (breast and prostate), AWV rates were
higher than those without cancer. AWV rates were high among individuals with breast (20%)
and prostate (19%) cancer, followed by uterine cancer (16%) and NHL (13%). The lowest rates
were among individuals with ovarian cancer (7.5%).
Model Performance
We compared the model performance metrics between traditional logistic regression and
the XGBoost model, and the ML model outperformed logistic regression with respect to model
accuracy, sensitivity, specificity, and AUC (Table 3). The logistic regression model had (60%)
recall, (60%) specificity, (60%) accuracy and (64%) AUC, while the XGBoost model had (62%)
recall, (60%) specificity, (62%) accuracy and (71%) AUC.
Association of cancer to AWV.
Based on the SHAP summary plot (Figure 2), we observed that FCI, age, median income,
and county-level 3-year cancer mortality were the top four predictors of AWV. The features are
ordered in descending order of importance based on the mean SHAP value. Each point on the
plot represents an observation in the data; the x-axis value indicates the effect of the feature on
the final prediction; negative values mean a negative association with AWV, while positive
values have a positive association with AWV and increase the prediction. The color gradient
represents the value for that feature, with yellow corresponding to lower values of the feature and
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purple corresponding to higher values. The mean SHAP value for that feature is presented on the
left next to the feature label.
Using SHAP dependence plots (Figure 1), we observed that the association of cancer to AWV
varied by cancer type. There were no significant associations between breast and prostate cancer
and AWV, and the effect on AWV ranged between a 5% increase and a 5% decrease in the
likelihood of AWV. Colorectal, ovarian cancer, and NHL were associated with AWV.
Other predictors of AWV.
The other top predictors were the number of chronic conditions, county-level Medicare
advantage penetration, and county-level rates of Medicare and Medicaid dual eligibility.
Interactive effects of cancer on AWV
Table 3 shows the H-statistic for the features with the most significant interactions with
all other features. FCI, age and median income, and the number of chronic conditions were the
top interacting features. The feature interactions differed significantly by cancer type and gender.
For example, men with colorectal cancer under 80 years were more likely to have AWV
compared to men with colorectal cancer over 80 years. The distribution of FCI values for both
men and women with colorectal cancer clustered around (0.50 - 0.72). Individuals with
colorectal cancer and FCI over 0.5 were more likely to have AWV compared to the non-cancer
cohort. For the breast cancer cohort, the interaction between age and breast cancer was also
complex. Women under 80 years with breast cancer were more likely to have AWV compared to
women over 80 years with cancer. Women with breast cancer over 80 years were also less likely
to have AWV compared to the non-cancer cohort. Similar interactions between cancer and age
were also observed for the NHL cohort.
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3.5 Discussion
In this first nationwide study using a large nationally representative cancer registry to
examine the association of cancer to AWV among adults over 65 years, only one in five eligible
adults received an AWV in 2015. This estimate is consistent with the rates reported in previous
studies of between 7.5% to 20% among Medicare beneficiaries.45,127,129 The AWV rates within
our non-cancer cohort were also consistent with published literature.45,126,130 However, no
previous studies have reported AWV rates among cancer patients. These low AWV utilization
rates are concerning, and some qualitative studies that aimed to understand the factors
influencing AWV rates have reported that patients may be confused about the distinctions
between regular visits and AWV, which may contribute to the low utilization rates.131 Other
studies suggest that patients are less likely to use AWV if they perceived that their chronic illness
concerns are not addressed during a wellness visit.131 Some authors have suggested that
physician recommendation is vital to increasing patient participation in AWV.132 However, some
physicians may be unable to rely on their EHRs to proactively identify eligible patients and offer
AWV to them. In addition, only about 10% of clinicians currently offer AWVs within their
services.133 Additional interventions targeting patients with telephone or mail-in reminders134 and
public informational sessions135 need to be promoted to increase AWV uptake. Pharmacistsled136,137 and nurse-led138,139 interventions can be explored in areas with physician shortages to
complement the efforts of primary care physicians. Also, since the AWV does not usually
require an in-person visit by the patient (except in an FQHC/RHC setting), telehealth or virtual
visits may be one of the pathways to increase the AWV. 132
The association of cancer to AWV varied by cancer type; for breast and prostate cancers,
AWV rates were higher than the non-cancer cohort; for colorectal and NHL cancers, AWV rates
were lower than the non-cancer cohort. We speculate that the differences in the relationship
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between different cancers and AWV may reflect variations in the patient populations, prognosis,
clinical priorities, and healthcare utilization between the cancer types.
Consistent with published literature, we found that predisposing characteristics such as
age, race, urban-rural residence, and income were significant predictors of AWV.45,140 This
study’s finding that Non-Hispanic whites were more likely to have AWV compared to Hispanic
and African American beneficiaries is consistent with previous literature that reported racial
variations in the rates of AWV.127,129,140 We also found that older age was negatively associated
with AWV, and adults over 80 years were less likely to have AWV compared to younger
individuals.
The regional and rural-urban differences in the rates of AWV have been previously
reported,141 and plausible explanations for these variations may be related to rural-urban
variations in the rates of uptake and adoption of new guidelines and policies.142,143 Previous
studies had reported low uptake and adoption rates of other Medicare preventive care benefits
such as the “welcome visit” when it was first introduced mostly due to lack of awareness.144,145
The leading patient-level predictors of AWV identified by the XGBoost model include
FCI, age, and median income. The relationship between age and AWV was complex and nonlinear; between ages 66 and 70 years, increasing age was positively associated with AWV.
However, this relationship was reversed between the ages of 70 to 75 and also for those over 80
years. The relationship between median income and AWV was inverse and non-linear for all
beneficiaries with income below $100,000. However, above $100,000, there was a positive
linear relationship between median income and AWV, and increasing income increased the
likelihood of AWV. This complex relationship may reflect the disproportionate impact of limited
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resources and socioeconomic factors on access to preventive healthcare and health service
utilization, which in turn leads to disparities in health outcomes.
A noteworthy finding is the association of market characteristics to AWV; specifically,
the county-level 3-year cancer mortality rate was highly associated with AWV. Individuals
residing in counties with higher cancer mortality rates were 20% less likely to have AWV. This
finding is important because it suggests poor health outcomes among individuals who do not
receive AWVs and may signal major disparities in access to preventive services. A previous
study by Camacho et al. reported that AWV was effective in increasing evidence-based
preventive service utilization such as vaccines and screenings,43 other studies have reported
improvements in multiple healthcare quality measures and reduced healthcare costs.146 Higher
Medicare advantage penetration rates were also associated with a higher likelihood of AWV.
Previous studies have reported higher early adoption rates for AWV within managed care and
accountable care organizations,45 which may signify higher motivation for preventive health
practices for physicians within these practice groups. These findings are consistent with previous
literature that found that individuals with Medicare supplementary insurance were more likely to
use preventive services,145 while dual-eligible beneficiaries were less likely to use preventive
services.147 We speculate that these area-level effects may be related to the spillover effects of
managed care on physician practices.112 Higher Medicare advantage and managed care
penetration in an area can affect physician practice patterns both for managed care and fee-forservice patients; the ensuing spillover of some managed care policies eventually benefits all
patients in their care.113 Previous research suggests that this “spillover” may be substantial when
managed care patients comprise a significant proportion of physicians’ or hospitals’
practice.113,114 These disparities may also be exacerbated by health system practices like “ACO
Cherry picking” which appears to target their “attributable beneficiaries” to receive AWV since
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those select patients count towards the cost savings program in which the ACO’s participate. 148
Taken together, this study’s findings reveal that strategies aimed at improving quality of care and
outcomes among patients with cancer need to focus on increasing the utilization of preventive
services specifically, the AWV in this population.
3.6 Conclusion
In this first population-based study evaluating AWV in cancer patients, approximately
two out of 10 older fee-for-service Medicare beneficiaries had an AWV in 2015. Our findings
highlight very low uptake of AWV in older adults with and without cancer and, specifically, in
minority populations. The association of cancer to AWV varied by cancer type, suggesting that
interventions customized to specific types of cancers may be needed to improve the uptake of
AWV.
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Tables and Figures
Table 3.1: Description of Eligible Adults diagnosed with Breast,
Colorectal, Ovarian, Uterine, Prostate Cancers and NonHodgkin’s Lymphoma and Non-Cancer Control Group
SEER-Medicare, 2014 – 2015
Characteristics
N
Cancer status
Cancer
36477
Non-cancer
30607
Cancer Type
Breast Cancer
11140
Colorectal Cancer
7439
NHL
3664
Ovarian Cancer
1093
Prostate Cancer
10936
Uterine Cancer
2205
Non-cancer
30607
Gender
Female
38163
Male
28921
Age group
66-69 years
21379
70-74 years
16925
75-79 years
11463
≥80 years
17317
Race
White
54434
African American
5821
Others
6829
Region
Northeast
12475
South
15362
North Central
6987
West
29717
Number of Physical Health Conditions
None
9777
1-2
20687
3 or more
36620
Rural/Urban residence
Metro
56862
Urban
8907
Rural
1247
Income
$8,650 - $37,401
11464
$37,404 - $49,340
11288
$49,360 - $62,486
10813
$62,487 - $84,239
10510
$84,289 - $250,014
11347
Annual Wellness Visit
Visit
11073
No Visit
56011

%
54.4
45.6
16.6
11.1
5.5
1.6
16.3
3.3
45.6
56.9
43.1
31.9
25.2
17.1
25.8
81.1
8.7
10.2
19.3
23.8
10.8
46.0
14.6
30.8
54.6
84.8
13.3
1.86
20.7
20.4
19.5
19.0
20.5
16.5
83.5

Continuous Variables

Mean

Standard
Deviation

Age at Index Date

75.35

7.69
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Fragmentation of Care Index
Number of Physical Health Conditions
3-Year Malignant Neoplasm Mortality
rate/100000
Medicare Advantage Penetration
Median Income
County-level Percent Medicare/Medicaid Dual
Eligibility

0.53
2.88
2125.9

0.21
2.02
3509.7

27.29
76693
23.83

13.03
20726
9.82

Note: Based on 67,084 adults over 66-years, diagnosed with breast, prostate, colorectal, uterine,
ovarian cancers, and non-Hodgkin’s lymphoma, living in any of the 18 SEER regions in the
United States, and non-cancer controls randomly drawn from Medicare enrollees in SEER
regions. All having continuous enrollment for 12 months baseline and 12months follow-up
periods. Physical health conditions measured include Asthma, Arthritis, Chronic obstructive
pulmonary disease, Chronic Kidney disease, Cardiac arrhythmia, Congestive heart failure,
hypertension, hyperlipidemias, Diabetes, hepatitis, dementia.
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Table 3.2: Description of Eligible Adults diagnosed with Breast,
Colorectal, Ovarian, Uterine, Prostate Cancers and NonHodgkin’s Lymphoma and Non-Cancer Control Group
SEER-Medicare, 2014 – 2015
Wellness Visit
No Wellness Visit
N
%
N
%

Characteristics
Cancer Status
Cancer
Non-cancer
Cancer Type
Breast Cancer
Colorectal Cancer
NHL
Prostate Cancer
Ovarian Cancer
Uterine Cancer
Non-cancer
Gender
Female
Male
Age Group
66-69 years
70-74 years
75-79 years
≥ 80 years
Race/Ethnicity
White
African American
Hispanic
Others
Region
Northeast
South
North Central
West
Rural/Urban residence
Metro
Urban
Rural
Median Income
$8,650-37,401
$37,404-49,34
$49,360-62,48
$62,487-84,23
$84,289 and above

5918
5010

16.4
16.6

30263
25172

83.6
83.4

2238
774
457
2021
82
346
5010

20.2
10.5
12.5
18.7
7.5
15.8
16.6

8828
6613
3186
8784
1009
1843
25172

79.8
89.5
87.5
81.3
92.5
84.2
83.4

6368
4560

16.8
16.0

31496
23939

83.2
84.0

3824
3174
1927
2003

18.4
18.8
16.9
11.6

17012
13669
9492
15262

81.6
81.2
83.1
88.4

9406
710
114
698

17.3
12.2
7.7
14.9

44990
5098
1360
3987

82.7
87.8
92.3
85.1

2521
2397
1232
4342

20.5
15.7
17.8
14.8

9791
12854
5683
25033

79.5
84.3
82.2
85.2

9672
1105
151

17.2
12.5
12.2

46606
7739
1090

82.8
87.5
87.8

1618
1588
1682
1716
2323

14.2
14.1
15.7
16.4
20.7

9810
9652
9053
8727
8916

85.8
85.9
84.3
83.6
79.3

Note: Based on 67,084 adults over 66-years, diagnosed with breast, prostate, colorectal, uterine,
ovarian cancers, and non-Hodgkin’s lymphoma, living in any of the 18 SEER regions in the
United States, and 30,607 non-cancer controls randomly drawn from Medicare enrollees in
SEER regions. All having continuous enrollment for 12 months baseline and 12months followup periods.
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Table 3.3: Model Performance for Logistic Regression and Machine Learning
Models for Prostate, Breast, Colorectal, and Non-Hodgkin Lymphoma.
Model Evaluation Metrics
Accuracy
Sensitivity
Specificity
AUC

SEER-Medicare, 2005 – 2015
Model
Logistic Regression
0.60
0.60
0.60
0.64

XGBoost
0.62
0.62
0.60
0.71

Note: Based on 67,084 adults over 66-years, diagnosed with breast, prostate, colorectal, uterine, ovarian cancers and
non-Hodgkin’s lymphoma, living in any of the 18 SEER regions in the United States, and 30,607 non-cancer controls
randomly drawn from Medicare enrollees in SEER regions. All having continuous enrollment for 12 months baseline
and 12months follow-up periods.

Table 3.4: Description of Eligible Adults
diagnosed with Breast, Colorectal, Ovarian,
Uterine, Prostate Cancers and NonHodgkin’s Lymphoma and Non-Cancer
Control Group
Feature

SEER-Medicare, 2014 – 2015
H-statistic

FCI

0.68

Age

0.60

Median Income

0.43

Number of Chronic Conditions

0.37

Medicare Advantage Penetration

0.31

ED Visits per 1000 Beneficiaries

0.29

Medicare-Medicaid Dual Eligibility

0.24

Medicare Beneficiary Hospital
Readmission Rate
3-Year Cancer Mortality Rate

0.23
0.21

Note: Based on 67,084 adults over 66-years, diagnosed with
breast, prostate, colorectal, uterine, ovarian cancers, and nonHodgkin’s lymphoma, living in any of the 18 SEER regions in
the United States, and 30,607 non-cancer controls randomly
drawn from Medicare enrollees in SEER regions. All having
continuous enrollment for 12 months baseline and 12months
follow-up periods.
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Fig 3.1: SHAP Dependence Plot for the Association of Cancer to AWV

Note: Brst = Breast cancer. clrl_m = Men with Colorectal cancer. clrl_f = women with colorectal cancer. uter = Uterine cancer. ovry = Ovarian
cancer. Prst = Prostate cancer. nhl_m = men with Non-Hodgkin’s lymphoma. nhl_f = women with non-Hodgkin’s lymphoma
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Fig 3.2: SHAP Summary Plot showing the Top 15 predictors of AWV

Note: Carefrag = Care Fragmentation. age_dx = Age at cancer diagnosis. Median_inc = Median Income.
Mortality3YrMalignantNeoplasm = county level 3-year cancer mortality. MedicareAdvantagePenetration = Medicare
Advantage penetration. MecrBenefEligMedcaid = Dual Medicare and Medicaid eligible individuals.
EDVisitsper1kBenef = county level Emergency department visits per 1000 beneficiaries. Phc_nbr = Number of preexisting chronic conditions. MedcreBenef_Hosp_ReadmissRate = County level Medicare beneficiary hospital
readmission rate. FedQualifiedHealthCenters = county level number of Federally qualified health centers. Brst =
Breast cancer. Prst = Prostate cancer.
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CHAPTER 4
Low-Value Care and Excess Out-Of-Pocket Expenditure Among Older Adults with
Incident Cancer.
4.1 Abstract
Objective: To evaluate the association of low-value care with excess out-of-pocket expenditure
among older adults diagnosed with incident breast, prostate, colorectal cancers, and NonHodgkin’s Lymphoma.
Methods: We used a retrospective cohort study design with 12-month baseline and follow-up
periods. We identified a cohort of older adults (age ≥ 66 years) diagnosed with breast, prostate,
colorectal cancers, or Non-Hodgkin’s lymphoma between January 2014 and December 2014. We
assessed low-value care and patient out-of-pocket expenditure in the follow-up period. We
identified relevant low-value services using ICD9/ICD10 and CPT/HCPCS codes from the
linked health claims and patient out-of-pocket expenditure from Medicare claim files and
expressed expenditure in 2016 USD.
Results: About 29% of older adults received at least one low-value care procedure. In the
follow-up period. Low-value care differed by gender, and rates were higher in women with
colorectal cancer (32.7%) vs. (28.8%) and NHL (40%) vs. (39%) compared to men. Individuals
who received one or more low-value care had significantly higher mean out-of-pocket
expenditure ($8,726±$7,214) vs. ($6,802±$6,102). xgboost, a machine learning algorithm,
revealed that low-value care was among the five leading predictors of OOP expenditure.
Conclusion: One in four older adults with incident cancer received low-value care in 12-months
after a cancer diagnosis. Across all cancer populations, individuals who received low-value care
had significantly higher out-of-pocket expenditure. Excess out-of-pocket expenditure was driven
by low-value care, fragmentation of care, and an increasing number of pre-existing chronic
conditions.
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4.2 Introduction
In the United States (US), over 25% ($955 billion) of annual healthcare spending is
considered wasteful because it is spent reimbursing low-value care.1,2 Low-value care refers to
the provision of healthcare services, medical tests, and procedures that have unclear or no
clinical benefit to patients.3 Low-value care includes both overuse and overtreatment – defined as
care that is inappropriate or care that may be inappropriate only under certain circumstances.8
World-wide, low-value care imposes a significant economic burden for patients, payers,
governments, and society.5 Previous studies have reported the excessive economic burden of
low-value care on payers and government,16,22,71,72 but there is limited literature on the economic
burden to patients, specifically the out-of-pocket spending associated with low-value care. In
Minnesota, 18 low-value care services accounted for $54.9 million spent in 2014, and 16.9%
($9.3 million) of that expenditure was borne out-of-pocket by patients.149 Kao-ping et al.
evaluated 20 pediatric low-value services and reported that 33.9% ($9.3 million) of the overall
expenditure was paid out-of-pocket.150 No previous studies have estimated the economic burden
of low-value care among cancer patients > 65 years.
Cancer care among older adults > 65 years is one of the biggest drivers of healthcare
expenditure in the US and accounts for nearly 40% of all spending.23 Low-value care among
cancer patients contributes to the financial toxicity of cancer treatment.151 However, most studies
on the financial toxicity of low-value care among cancer patients focus on expensive cancer
therapy and do not explore the toxicity associated with non-cancer low-value care received for
pre-existing chronic conditions. Examining the relationship between low-value care and out-ofpocket expenditure among cancer patients will provide meaningful data for policymakers on the
economic impact of low-value care in elderly Medicare beneficiaries and help drive efforts to
improve quality. This study aims to evaluate the association of low-value care to out-of-pocket
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expenditure among patients diagnosed with incident breast, prostate, colorectal cancers, and
Non-Hodgkin’s Lymphoma.
4.3 Methods
Data Source:
We used data from multiple sources for this study. We combined data from the
Surveillance, Epidemiology, and End Results (SEER) registry, Medicare claims (inpatient,
outpatient, physician services, and home health agency claims), Area Health Resources File
(AHRF), census data, and 5% non-cancer sample from the SEER regions. The SEER Program is
a population-based tumor registry that collects data on all incident cases of cancer in persons
residing in the 18 SEER regions. SEER cancer registry regions include (Atlanta, Connecticut,
Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los
Angeles and San Jose-Monterey, Rural Georgia, Alaska Native, Greater California, Kentucky,
Louisiana, New Jersey, and Greater Georgia).
Study Design:
We adopted a retrospective cohort study design with 12-month baseline and follow-up
periods for this study. The index date was anchored to the date of cancer diagnosis, and the 12month pre-diagnosis period was used as the baseline. We measured all the independent variables
during this baseline period. We assessed low-value care and out-of-pocket expenditure in the 12month follow-up period. The study cohort consisted of older adults (age ≥ 66 years) diagnosed
with breast, prostate, colorectal cancers or Non-Hodgkin’s lymphoma between January 2014 and
December 2014. To be included in this study, Medicare beneficiaries were required to have one
primary cancer diagnosis, be alive during the calendar year, and the cancer was not diagnosed
from an autopsy report or death certificate. We included fee-for-service beneficiaries with
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continuous Part A and B enrollment during the study period and without HMO plan enrollment
in the baseline and follow-up periods.
Measures
Target Dependent Variable
Out-of-pocket expenditure: We identified all payments made by the patients for services
obtained. Out-of-pocket payments included patient deductible, coinsurance, and blood
deductible amounts. We assessed low-value care specific out-of-pocket expenditure as well as
the total out-of-pocket expenditure. We measured the total out-of-pocket expenditure for the
cohort by adding the patient deductible amounts with patient co-payments and any other
payments covered by the beneficiary using the already validated methodology described by
ResDAC.152 We obtained all payment amounts from Medicare inpatient, outpatient, emergency
room, home health agency, and durable medical equipment files. All healthcare expenditure was
converted to real dollars using the consumer price index for medical services and expressed in
2016 USD.
Key Feature:
Low-value care: Low-value care services were identified using previously published
methodology by Schwartz et al.74 and Colla et al.71 that represent some of the published
Choosing Wisely recommendations. For each indicator procedure, we identified instances where
the use of the procedure was most likely to be low-value because they were not clinically
indicated. We used ICD9/ICD10 and CPT/HCPCS codes to identify relevant procedures from
the inpatient, outpatient, physician, and home health agency files.
Other Features:
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The selection of features was guided by published literature and the WHO cost of illness
framework153 The theory assumes that healthcare utilization provides a level of utility to the
consumer and leads to healthcare expenditure. The model takes into consideration both clinical
and social determinants using a bottom-up approach to estimate expenditures and regards
expenditures as the outcome of the healthcare process. Social determinants include factors like
demographics (age at index date (66-69, 70-74, 75-79, or >=80 years); sex -male or female; race
-Non-Hispanic White, Non-Hispanic African American, Latinx, or others), geography,
(Northeast, South, North-Central, or West; rural/urban -metro, urban, or rural), socio-economic
and access factors (zip-code level income and education, county-level Medicare and Medicaid
dual eligibility), access to care (30-day readmission rates, emergency department visits per 1000
population, 3-year malignant neoplasm mortality rates, Medicare advantage penetration).
Clinical factors include health status (chronic conditions including asthma, arthritis, chronic
obstructive pulmonary disease, diabetes, coronary artery disease, congestive heart failure,
hypertension, hyperlipidemia, chronic kidney disease; mental health conditions included
dementia, bipolar disorder, depression, or anxiety), patient-level fragmentation of care,
preventive services use and healthcare utilization. Fragmentation of care was measured using a
claims-based fragmentation of care index (FCI).76 FCI measures the dispersion of care across
multiple providers and specialties; preventive service use consisted of receiving influenza
vaccination, and healthcare use was measured with ED and inpatient visits.
Analysis
Statistical analysis methods have historically been used to examine the relationship
between risk factors (independent variables) and outcomes using a small number of clinically
important variables and produce “clinician-friendly” measures of association like risk or odds
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ratios that are easy to interpret. These statistical models have some limitations regarding the
strict assumptions about the distribution and shape of the data, including proportional hazards,
additivity, and probability distribution of errors. These assumptions are often not met in clinical
practice, and violating these assumptions often renders the model inaccurate.
ML methods offer a flexible and adaptive alternative to statistical modeling because they
do not rely on distributional assumptions. ML algorithms typically use recursive partitioning
techniques to split original data into training validation and test datasets. ML algorithms learn
associations in the data using the training set and make predictions on the “unseen” test data.
We built two ML models to assess the predictors of out-of-pocket expenditure; the first model
was built using xgboost regression with log-transformed expenditure, while the second model
was built using xgboost Tweedie regression using non-transformed expenditure. The Tweedie
distributions are a special case of exponential distributions with “point mass” at zero and are
helpful for modeling expenditure in datasets where most observations have zero expenditure.154
We evaluated the performance of our models using root mean square error (RMSE) and mean
absolute error (MAE). To interpret our models, we use the Shapely Additive explanations
(SHAP) explanation technique developed by Lundberg et al.82 SHAP values assess the
importance of a feature by comparing the model prediction when the feature is present and when
it is removed from the model. We also used SHAP accumulated local effect plots and partial
dependence plots to explore the marginal effects of the top predictors of out-of-pocket
expenditure.
4.4 Results
The study cohort comprised 27,067 eligible older adults who met all the inclusion
criteria. About 29% of the individuals received at least one low-value care procedure in the
follow-up period. A description of the cohort characteristics for adults with and without low67

value care is presented in (Table 1). The majority of the cohort were female (52%), white (83%),
lived in metro areas (84%), and had three or more pre-existing chronic conditions (59%). The
most common chronic conditions include hypertension (79%), hyperlipidemia (70%), and
arthritis (27%). The most common mental health condition was depression (10%). The mean age
at cancer diagnosis was (76 ± 7.02) for the low-value care group and (75±6.72) for those
without low-value care. The mean fragmentation of care index among individuals who received
low-value care was (0.62 ± 0.11) vs. (0.60 ± 0.12) for those without low-value care. The mean
number of chronic conditions was higher for the low-value care group (3.67 ± 1.96) vs. (2.78 ±
1.74) for those without low-value care. Low-value care rates varied by gender for some cancers
(NHL and colorectal cancer); Low-value care was higher in women with colorectal cancer
(32.7%) vs. (28.8%) compared to men with colorectal cancer. We also observed the highest rates
of low-value care in women with NHL (40%) vs. (39%) for men with NHL.
Out-of-Pocket Expenditure Individuals who received one or more low-value procedures
had significantly higher mean out-of-pocket expenditure ($8,726±$7,214) vs. ($6,802±$6,102)
compared to those who did not have low-value care in the follow-up period. Within all cancer
types, individuals who received low-value care had higher out-of-pocket expenditure. The
highest mean out-of-pocket expenditure was observed in individuals with NHL and low-value
care ($13,554) vs. ($11,698) for those without low-value care. The mean expenditure for breast
cancer patients without low-value care was ($6,940±5,780) vs. ($8,412±6,398) for those who
had low-value care. The mean expenditure for prostate cancer patients without low-value care
was ($5,234±4,238) vs. ($6,878±5278) for those who had low-value care. The mean expenditure
also differed by gender for individuals with colorectal cancer; for men with colorectal cancer, the
mean out-of-pocket expenditure for those without low-value care was ($8,102±7220) vs.
($9,557±8,299) for those who had low-value care. For women with colorectal cancer, the mean
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out-of-pocket expenditure for those without low-value care was ($7,064±6,043) vs.
($8,842±7,067) for those who had low-value care. Out-of-pocket expenditure did not differ
significantly between men and women with NHL and low-value care ($13,564 vs. $13,540),
respectively.
Model Performance
We compared the model performance metrics [Root Mean Square Error (RMSE) and rsquared] between the xgboost regression using log-transformed expenditure with xgboost
Tweedie regression. The log-transformed model performed better (RMSE = 0.52, R2 = 0.83)
than the Tweedie regression (RMSE = 632, R2 0.71).
Leading predictors of out-of-pocket expenditure
Figure 1 shows the SHAP summary plot for leading predictors of out-of-pocket
expenditure. Each point on the plot represents an observation in the data; the x-axis value
indicates the effect of the feature on the final prediction, negative values indicate a negative
association with out-of-pocket expenditure while positive values increase out-of-pocket
expenditure. The color gradient represents the value for that feature, with yellow corresponding
to lower values of the feature and purple corresponding to higher values. The features are
ordered in descending order of importance based on the mean SHAP value. Based on the SHAP
summary plot, we observed that cancer, low-value care, number of physical health conditions,
and FCI were the top predictors of excess out-of-pocket expenditure. Low-value care increased
out-of-pocket expenditure by 5%
Using SHAP dependence plots (Figure 2), we observed that low-value care increased the
out-of-pocket expenditure by $2,000 and up to $4000 for some individuals. The accumulated
local effect plots (Figure 3) show the association of age, number of physical health conditions,
FCI, and median income with out-of-pocket expenditure. The relationship between FCI and
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expenditure was complex; for values between (0 – 4) and (6 – 8), increasing FCI was associated
with higher out-of-pocket expenditure. However, this association was negative for FCI values
between 4 and 6. There was an inverse relationship between age and out-of-pocket expenditure,
younger adults had higher out-of-pocket expenditure compared to older adults, and adults over
90 years had on average $2,500 less out-of-pocket expenditure. There was a positive relationship
between the number of chronic conditions and out-of-pocket expenditure, and an increasing
number of chronic conditions increased expenditure.
The features with the largest interactions with all other features were FCI, age, median
income, and the number of chronic conditions. The feature interactions differed significantly by
cancer type. For example, individuals with prostate cancer under 75 years had lower out-ofpocket costs compared to the rest of the cohort. However, above 75 years, the out-of-pocket costs
increased by about $500-$1,000 over the rest of the cohort. The effect of higher care
fragmentation on out-of-pocket expenditure was observed to be significant for FCI values above
0.6 and increases out-of-pocket spending by $500 for every unit increase in FCI. The interaction
between low-value care and cancer type varied with the type of cancer (plots not shown) having
low-value care induced a wider variation in expenditure compared to individuals without lowvalue care for all the cancers.
4.5 Discussion
In this first nationwide study of the excess cost burden of low-value care on cancer
patients, one in four older adults with cancer received at least one low-value care procedure. The
prevalence rates of low-value care differed by cancer type, with the highest rates in patients
diagnosed with incident NHL (40%) followed by colorectal cancer (33%), breast cancer (28%),
and prostate cancer (27%). The rates of low-value care observed in our study is broadly
consistent with previous estimates of low-value care in the Medicare population.32,71,72,75
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Low-value care was associated with higher out-of-pocket expenditure. We observed that
low-value care was driving the excess out-of-pocket expenditure across all cancers after
adjusting for other factors. On average, patients who received a low-value procedure experienced
between $1,000 and $2,000 higher out-of-pocket expenditure attributable to low-value care. This
finding is important because it focuses on the excess cost burden associated with low-value care
in cancer patients and its contribution to financial toxicity in these patients. To address this
problem of low-value care and its associated economic burden, multi-pronged interventions
targeting patients, physicians, and payers need to be deployed. Patient-focused interventions
employing quality metrics and tiered benefit plans155 that lower patient cost-sharing for receiving
care from providers and organizations reporting higher quality metrics are needed to help address
this problem.156 Previous studies report that patients rarely utilize these reported quality metrics
when making decisions about where to receive care,157 primarily because the reports are prepared
using technical language that is not easily comprehensible for most patients.158–160 Providerfocused interventions that inform physicians of the possible out-of-pocket expenditure to patients
for specific low-value care have also been effective at reducing low-value care.161
This study’s finding that care fragmentation is a top predictor of out-of-pocket
expenditure is consistent with previous studies that have established that cancer care in patients
with multiple pre-existing chronic conditions is fragmented,162, and often occurs in silos.162–164
Patients with cancer and pre-existing chronic conditions frequently report negative experiences
with cancer care due to poor care coordination, medication errors, and financial concerns.165,166
Fragmented care frequently results in other chronic health needs unintentionally “falling through
the cracks” due to poor communication between primary care providers and oncology teams,167
resulting in adverse drug reactions, uncontrolled chronic illness, and excess out-of-pocket
expenditure.168,169 Also, some patients felt providers did not fully review their health records
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before their appointment and they were asked for the same medical information repeatedly,165
creating the impression that the provider did not have a clear overview of the patient's overall
medical situation. Effective care coordination that involves the primary care physician from the
point of diagnosis through the entire care trajectory is needed to improve outcomes.168 Snyder et
al. found that one in five cancer survivors never had a primary care provider visit in the second
year following a cancer diagnosis; such gaps in care could result in unmet chronic health needs
and an exacerbation of existing chronic conditions.170 In addition, robust clinical guidelines for
the management of multiple chronic conditions during cancer treatment and cancer survivorship
need to be developed. Current guidelines for the management of most chronic conditions exist in
silos within the specialty it was developed and do not account for chronic management during
cancer survivorship.52,53
This study’s finding that out-of-pocket spending declined with increasing age is broadly
consistent with previous reports that out-of-pocket expenditure initially increases with advancing
age then decreases,171 although some other studies have reported increasing out-of-pocket
expenditure with increasing age in patients with multiple health conditions.172 We also observed
this positive association between the number of chronic conditions and out-of-pocket
expenditure in this study. Expenditure remained relatively unchanged between one and four
chronic conditions but increased dramatically in individuals with five or more chronic
conditions.
Strengths and limitations
This is the first population-based study to quantify the direct economic impact of noncancer low-value care in older adults diagnosed with cancer and fills a critical gap in the
literature. This study uses real-world data from a nationally representative patient registry
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representative of adults over 65 years with cancer. We employed advanced machine learning
algorithms to identify the leading predictors of the excess cost burden and used model agnostic
explanation tools to explain the machine learning predictions.
This study has several limitations; like all direct measures of low-value care, our
estimates may be limited because of the quality of available data. Furthermore, there is a
potential for misclassifying some instances of low value-care in instances where care was
appropriate and high value because of the lack of more detailed clinical information often
required to make treatment decisions. We were only able to measure a limited number of the
over 150 low-value care services in the choosing wisely recommendations because some of the
recommendations on the list cannot be measured using the available data, so we may not have
captured the most important low-value services for health system efficiency and patient
outcomes
4.6 Conclusion
One in four older adults received low-value care in the follow-up period. Across all cancer
populations, individuals who received low-value care had significantly higher out-of-pocket
expenditure. Excess out-of-pocket expenditure was driven by low-value care, fragmentation of
care, and a higher number of pre-existing chronic conditions. Policy initiatives that target lowvalue care and fragmented care may reduce the financial burden on the payers as well as patients.
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Table 4.1: Description of Eligible Adults diagnosed with Breast,
Colorectal, Ovarian, Uterine, Prostate Cancers and Non-Hodgkin’s
Lymphoma by Low-value care category
Characteristic

SEER-Medicare, 2014 – 2015
Low-value care
N
%

Cancer Type
Breast
Colorectal
Prostate
Non-Hodgkin’s
Lymphoma
Gender
Female
Male
Age Group
66-69 years
70-74 years
75-79 years
≥ 80 years
Race/Ethnicity
White
African American
Others
Marital Status
unmarried
married
Separated/Widowed/Divor
ced
Preventive Influenza Vaccination
Preventive Flu shot
No preventive Flu
Region
Northeast
South
North Central
West
Rural/Urban Residence
metro
Urban
Rural
Cancer Stage
Stage 1
Stage 2
Stage 3
Stage 4
Unknown
Chemotherapy
Chemotherapy
No Chemotherapy
Number of Chronic Conditions
None
one-two
three or more
Income
$8,650-37,401

No Low-value care
N
%

2764
1620
2510

35.0
20.5
31.8

7208
3367
6863

38.1
17.8
36.2

995

12.6

1495

7.9

4170
3719

52.9
47.1

9776
9157

51.6
48.4

1706
2159
1746
2278

21.6
27.4
22.1
28.9

5256
5674
3896
4107

27.8
30.0
20.6
21.7

6653
694
542

84.3
8.8
6.9

15785
1679
1469

83.4
8.9
7.8

675
4118

8.6
52.2

1616
10412

8.5
55.0

3096

39.2

6905

36.5

4541
3348

57.6
42.4

10093
8840

53.3
46.7

1767
1774
927
3421

22.4
22.5
11.8
43.4

3692
4770
2151
8320

19.5
25.2
11.4
43.9

6893
872
124

87.4
11.1
1.6

15774
2789
370

83.3
14.7
2.0

2313
2976
874
876
850

29.3
37.7
11.1
11.1
10.8

5760
7827
2029
1711
1606

30.4
41.3
10.7
9.0
8.5

1875
6014

23.8
76.2

3942
14991

20.8
79.2

445
1767
5677

5.6
22.4
72.0

1885
6891
10157

10.0
36.4
53.6

1453

18.8

3816

20.6

74

$37,404-49,34
$49,360-62,48
$62,487-84,23
$84,289-250,0

1536
1495
1525
1727

Mean

Total Medicare Expenditure
Total Out-of-pocket Expenditure

$49,31
2
$8,726

19.9
19.3
19.7
22.3

3845
3492
3608
3798

20.7
18.8
19.4
20.5

Standard
Deviation

Mean

Standard
Deviation

$49,669
$7,214

$32,513
$6,802

$32,773
$6,102

Note: Based on 27,067 adults over 66-years, diagnosed with breast, prostate, colorectal, and nonHodgkin’s lymphoma, living in any of the 18 SEER regions in the United States. All having
continuous enrollment for 12 months baseline and 12months follow-up periods. Physical health
conditions measured include Asthma, Arthritis, Chronic obstructive pulmonary disease, Chronic
Kidney disease, Cardiac arrhythmia, Congestive heart failure, hypertension, hyperlipidemias, Diabetes,
hepatitis, dementia.
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Table 4.2: Parameter Estimates from Unadjusted and Adjusted Generalized Linear Models on Out-ofpocket Expenditure among Elderly Medicare Fee-for-service Beneficiaries with Incident Breast, Colorectal,
Prostate and Non-Hodgkin’s Lymphoma
SEER-Medicare data, 2014-2015 (n=26,590).
Parameter
Parameter
Change #
Change #
Estimate (SE)
Estimate (SE)
Unadjusted Models
Adjusted Model 2
Low-value care‡
Intercept

8.82 (0.006)

$6,796.72

8.83 (0.03)

$6,857.32

One or more LVCs

0.24 (0.01)

$8,725.87

0.19 (0.01)

$8,327.25

Intercept

8.58 (0.02)

$5,323.46

8.83 (0.03)

$6,857.32

Incremental

0.05 (0.00)

$5,614.03

0.03 (0.00)

$7,119.97

Intercept

8.8 (0.01)

$6,608.36

9.2 (0.03)

$6,857.32

Incremental

0.03 (0.01)

$6,841.60

0.02 (0.00)

$7,011.56

Care fragmentation

Number of Chronic conditions

Note: Based on 26,590 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment in Medicare part A & Part B, diagnosed
with Breast, Colorectal, Prostate, and NHL between January 2014 and December 2014. Out-of-pocket expenditures include inpatient, outpatient, durable
medical equipment, and home health agency costs.
‡Composite measure for individuals who received any one of the 20 measured low-value services.
Change # was calculated by the difference between the 1) exponentiation of the model intercept term and 2) the sum of the intercept and the variable
parameter estimate.
Compare to omitted category
SE= Standard Error, SEER= Surveillance, Epidemiology and End Results Cancer Registry
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Figure 4.1: SHAP Summary Plot for Top 15 predictors of Out-of-pocket Expenditure

Note: Carefrag = Care Fragmentation. age_dx = Age at cancer diagnosis. Median_inc = Median Income.
Mortality3YrMalignantNeoplasm = county level 3-year cancer mortality. MedicareAdvantagePenetration = Medicare
Advantage penetration. MecrBenefEligMedcaid = Dual Medicare and Medicaid eligible individuals.
EDVisitsper1kBenef = county level Emergency department visits per 1000 beneficiaries. Phc_nbr = Number of preexisting chronic conditions. MedcreBenef_Hosp_ReadmissRate = County level Medicare beneficiary hospital
readmission rate. FedQualifiedHealthCenters = county level number of Federally qualified health centers. Brst =
Breast cancer. Prst = Prostate cancer.
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Figure 4.2: SHAP Dependence Plot for the Association of Low-value care with Out-of-pocket
Expenditure
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Figure 4.3: Accumulated Local Effect Plot for association between features and Out-of-pocket
Expenditure

Note: Carefrag = Care Fragmentation. age_dx = Age at cancer diagnosis. Median_inc = Median Income. Phc_nbr =
Number of pre-existing chronic conditions.
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CHAPTER 5
5. Summary and Conclusion
5.1 Summary of Findings and Discussion
This dissertation focuses on health policy issues, specifically value-based care. Valuebased care is the cornerstone of achieving the triple aims of “better health, better value, and
lower costs.” Value-based care is defined as “A healthcare delivery model in which providers,
including hospitals and physicians, are paid based on patient health outcomes.”173 Under valuebased care agreements, physicians and providers are rewarded for helping patients improve their
health, minimize the effects and incidence of chronic disease, and live healthier lives in an
evidence-based way.173
Value-based care spans the spectrum of reducing low-value care as well as promoting
high-value care. As stated in the introduction and the three dissertation studies, low-value care is
defined as the utilization of healthcare services, medical tests, and procedures that have unclear
or no clinical benefit to patients but still exposes them to risk is highly prevalent. This
dissertation adopted the guiding principles of the Research Consortium for Healthcare Value
Assessment framework and identified low-value care services that were easy to measure with
claims data, with robust clinical evidence and applicability across patients.174 The Annual
Wellness Visit (AWV) is recommended by the US preventive services task force (USPSTF)121
because of its effectiveness in improving preventive care,43 healthcare quality,122 and reducing
costs.122 Therefore, this was chosen as an indicator for high-value care. By focusing on lowand high-value care, the three studies of this dissertation were able to identify actionable
opportunities to reduce low-value and increase high-value care. This dissertation also used a
highly innovative approach and provided an artificial intelligence-powered insight to tackle the
provision of value-based care and promote high-value care.
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The findings from this dissertation have important clinical and policy implications for
various stakeholders in healthcare. Specifically, the Centers for Medicare and Medicaid Services
(CMS), with over 65 million enrollees, has issued a roadmap for states to accelerate the adoption
of value-based care, with the Department of Health and Human Services (HHS) setting a goal of
converting 50% of traditional Medicare payment systems to alternative payment models tied to
value-based care by 2022.175
In this first nationwide study of leading predictors of low-value care using machine
algorithms, we identified several key factors that could be modified to accelerate the adoption of
value-based care in Medicare. We observed that one in four adults received at least one of the 20
measured low-value care services, indicating that low-value care is a significant problem within
this population and that targeted interventions are needed. A systematic review of interventions
to reduce low-value care suggests multiple effective strategies or pathways. These include
provider-led interventions that engage patients and families in defining, identifying, and
communicating about low-value care,95 Informational campaigns to change patients' perceptions
and behavior,96–98 clinical decision support, clinician education,99–102, and risk-sharing payment
reforms.103
In this dissertation, the prevalence rates of low-value and high-value care differed by
cancer type. Older adults diagnosed with incident NHL and colorectal cancers were more likely
to receive low-value care. Those diagnosed with incident breast and prostate cancers were less
likely to receive low-value care. These differences in the relationship between cancer and lowvalue care may be due to variations in the patient populations, survival prognosis, clinical
priorities, and approach to managing co-occurring chronic conditions. Providers may feel
pressured to manage cancer as well as physical conditions and may order more tests rather than
having patient discussions that may be emotionally difficult for patients and their families.87
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Across all three studies, the leading patient-level predictors of the target variable were
care fragmentation, age, and the number of physical health conditions. The associations of these
variables to the target variables were non-linear and complex. Some of these predictors can be
targeted by intervention efforts to improve care quality. For example, fragmented care is
amenable to a modification by targeted interventions. However, such targeted interventions need
to consider the complex nature of the relationship. We speculate that for some individuals, the
FCI variable may reflect appropriate need, and seeking care from multiple providers may lead to
favorable outcomes, but for others, it may be harmful. Future studies need to unpack the benefits
of seeking care from multiple providers versus care fragmentation within fee-for-service
systems.
In our study, the ML algorithms not only confirmed the positive relationship between age
and the target variable but also highlighted the interactive relationship by cancer type. These
findings highlight the importance of including age in all the risk adjustment models.
This study confirmed the negative effects of multiple chronic conditions on target variables (lowvalue care, high-value care, and out-of-pocket expenditure). Older adults with multimorbidity
may be at increased risk of poor outcomes for several reasons; these may include “diseaseoriented” health system design,51 lack of robust clinical guidelines for the management of
multiple conditions,52,53 fragmentation of care,54,55 the over-cautious use of tests and therapies to
reduce potential risks,176 and lack of patient-engagement. 56
For patients with cancer and pre-existing multimorbidity, the competing demands of
cancer and concurrent chronic disease present unique challenges for treatment planning, care
coordination, and access.21 Notably, because of the life-threatening nature of the disease,46
provision of care by multiple providers,47 lack of communication between primary care providers
and oncologists,48–50 and lack of effective communication among care teams.177 50 These
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circumstances can predispose patients with cancer and multimorbidity to receipt of low-value
care.25
A noteworthy finding is the association of zip-code level social determinants to the target
variable. The relationships between education, median income, and the target variables were
complex. This complex relationship may be explained by the effects of patient socioeconomic
characteristics and access to healthcare on health service utilization.104–108 This finding
emphasizes the importance of integrating social determinants of health in interventions to reduce
the prevalence of low-value care in cancer and non-cancer patients. Recognizing the importance
of Social Determinants of Health (SDOH), healthy people 2030 features many objectives related
to SDOH, such as “Reduce the proportion of people living in poverty to 8% by the year 2030”,
and “Increase the proportion of high school completers who are enrolled in college to 73.7% by
2030”.178 Our findings also highlight the need for “health in all policies” (HiAP), an approach
that systematically and synergistically targets improved population health and equity in all
policies across health and non-health sectors.
This study also highlights the contribution of low-value care to financial toxicity in
cancer patients. Low-value care was the top predictor of excess out-of-pocket expenditure among
older cancer survivors. This finding emphasizes the need for patient-focused interventions using
quality metrics and tiered benefit plans155 that lower patient cost-sharing for receiving care from
providers and organizations reporting higher quality metrics.156
This study confirmed that fragmented care exposes patients and families to excess
economic burden and frequently results in other chronic health needs unintentionally “falling
through the cracks,” resulting in adverse drug reactions, uncontrolled chronic illness, and excess
out-of-pocket expenditure.168,169 Effective care coordination that involves the primary care
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physician from the point of diagnosis through the entire care trajectory is needed to improve
outcomes.168
Finally, in all three studies of this dissertation, machine learning algorithms outperformed the
standard statistical techniques. So our study provided evidence on the feasibility of machine
learning methods for evaluating health quality and outcomes.
5.2 Future directions
Although the present work focused on the prevalence and economic burden of low-value
care on patients, a more holistic approach that examines the humanistic, clinical, and social
burden is needed. Future studies using EHR data and machine learning approaches can further
characterize the processes of low- and high-value care delivery by incorporating clinical factors.
It has to be noted that using linked registry and claims data; this study did not control for
observable and unobservable selection bias in the evaluation of low- and high- value care, the
Covid-19 pandemic may have created a natural experiment to study the “real effects” of low- and
high-value care because, in many health systems, elective procedures were halted
instantaneously creating randomization of patients into low-value and no-treatment groups.
Future studies can employ “deep learning” AI methods to further elucidate the predictive
relationships between personal characteristics and low- and high-value care to personalize care
and intervention efforts.
5.3 Strengths and limitations
This is the first population-based study to examine the association of cancer and preexisting chronic conditions to low-value care and quantify the direct economic impact of lowvalue care on older adults diagnosed with cancer and fills a critical gap in the literature. This
study uses real-world data from a patient registry that is nationally representative of adults over
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65 years with cancer. We employed advanced machine learning algorithms to identify the
leading predictors of the excess cost burden and used model agnostic explanation tools to explain
the machine learning predictions.
This study has several limitations; like all direct measures of low-value care, our
estimates may be limited because of the quality of available data. Furthermore, there is a
potential for misclassifying some instances of low value-care in instances where care was
appropriate and high value because of the lack of more detailed clinical information often
required to make treatment decisions. We were only able to measure a limited number of the
over 150 low-value care services in the choosing wisely recommendations because some of the
recommendations on the list cannot be measured using the available data, so we may not have
captured the most important low-value services for health system efficiency and patient
outcomes
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Appendices

Supplement 1; List of Low-value healthcare services and procedures.
Low-value care
recommendation

CPT codes to
identify potential
low-value services

Population

Codes for Excluding
Beneficiaries

1.

Don’t screen women older
than 65 years for cervical
cancer who have had
adequate prior screening and
are not otherwise at high
risk for cervical cancer.179

Cervical screening;
G0123 G0124 G0141
G0143 G0144 G0145
G0147 G0148 P3000
P3001 Q0091

Female beneficiaries over
age 65 at low risk for
cervical cancer who
received at least one
cervical cancer screening
test for each calendar year.

2.

Don’t routinely repeat dual
energy x-ray absorptiometry
(DEXA) scans more often
than once every two
years.180
Initial screening for
osteoporosis should be
performed according to
National Osteoporosis
Foundation
recommendations.

Bone Density testing:
76070 76071 76075
76076 76078 76977
77078‐77081 77083
78350 78351

All beneficiaries

3

Do not refer for arthroscopic
lavage and debridement as
part of treatment for
osteoarthritis, unless the
person has knee
osteoarthritis with a clear
history of mechanical
locking (as opposed to
morning joint stiffness,
'giving way' or X-ray
evidence of loose bodies).183
Don’t do workup for
clotting disorder (order
hyper-coagulable testing)
for patients who develop
first episode of deep vein
thrombosis (DVT) in the
setting of a known cause.74

CPT: 29877 29879
29880 29881 G0289
(knee arthroscopy with
chondroplasty)

Chondromalacia,
Osteoarthritis (ICD-9: 7177
73392 71500 71509 71510
71516 71526 71536,
71596)

ICD‐9:180 184x 2190 2331 2332 2333x
6221 (cervical and other relevant cancers,
dysplasia’s) 7950x‐7951x (abnormal
Papanicolaou finding, human
papillomavirus
positivity) V1040 V1041 V1322 V1589
(history of cervical cancer, other relevant
cancers, dysplasia)
Hip fracture; CPT 27230-27248. Wrist
fracture; ICD-9 813.4-813.54, 814.00,
814.10 and CPT 25600, 25605, 25609,
25611. Humerus fracture; ICD-9 812.0812.19 and CPT 23600-23630, 2366523680.
Vertebral fracture; ICD-9 805.2. 805.4,
805.8, 733.13
Shoulder/clavicle imaging; CPT 73000,
73010, 73020, 73030, 73040, 73050
Humerus/elbow imaging; CPT 73060,
73070, 73080, 73085
Forearm/wrist imaging;
CPT
73090, 73092, 73100, 73110, 73115
Hand imaging; CPT 73120, 73130, 73140.
CT; CPT 73200, 73201, 73202, 73206
MRI; CPT 73218, 73219, 73220, 73221,
73222, 73223, 73225
Meniscal tear (ICD-9: 8360-8362 7170,
71741)

CPT: 81240 81241
83090 85300 85303
85306 85613 86147
(hypercoagulability
chemistries)

Stress echocardiography for
detection of CAD/risk
assessment in symptomatic
or ischemic equivalent acute
chest pain (i.e. Acute
Coronary Syndrome).184

Stress Echocardiography
CPT: 93350, 93351
HCPCS: C8928, C8930

ICD‐9: 4151 (pulmonary
embolism) 4510 45111
45119 4512 45181 4519
4534 4535
(phlebitis, thrombophlebitis
and venous embolism of
lower extremity vessels)
V1251, V1255 (history of
venous thrombosis and
embolism, pulmonary
embolism)
Individuals with a code for
emergency visit* with any
of the ICD-9 diagnoses OR
individuals with a
hospitalization with DRGs
as listed, or primary or
secondary diagnosis code
during hospitalization for
any of the ICD-9 diagnoses
ER visit
CPT 99281-99285

4

5

Diagnoses (associated with
ER visits or
Hospitalization)

99

Recurrent Deep Vein
Thrombosis/Pulmonary
Embolism (defined as a DVT/PE diagnosis
>90
days before the current diagnosis)

6

7

8

Laminectomy and/or spinal
fusion

Don’t routinely obtain
radiographic imaging for
patients who meet
diagnostic criteria for
uncomplicated acute
rhinosinusitis. 184
Do not perform routine
monitoring of digoxin in
patients with congestive
heart failure. 184

9

Don’t perform imaging of
the carotid arteries for
simple syncope without
other neurologic symptoms.

10

Don’t request serology for
Helicobacter pylori. Use the
stool antigen or breath tests
instead.184
Avoid CT scans of the head
in emergency department
patients with minor head
injury who are at low risk
based on validated decision
rules.184

11

Laminectomy
CPT: 22533, 22534,
22558, 22630
0275T
63005, 63012, 63017,
63030, 63035, 63042,
63047, 63200, 63267,
63272, 63173, 63185,
63190, 63191
ICD-9 procedure: 80.51,
81.06, 81.07, 81.08,
84.67, 84.65
DRG: 459, 460
Fiberoptic laryngoscopy
CPT: 31575, 31476,
31577, 31578, 31579

Any measure of digoxin
with no hospitalizations
or ER visits during that
year. CPT: 80162

EEG on the same claim
as diagnosis of syncope
or at any time during the
hospitalization with a
code for syncope EEG
ICD-9 procedure: 89.14
CPT: 3650F, 95812,
95813, 95816, 95819,
95822, 95827 (outpatient
Code indicating testing
for H. pylori CPT: 86677

MRI (brain)
CPT: 70551, 70552,
70553,

12

Don’t perform traction for
low back pain

Traction CPT: 97012,
97140
HCPCS: E0830

13

Don’t screen for carotid
artery stenosis in
asymptomatic adult
patients.184,185

CPT 93880 or 3100F,
36222, 36223, 36224,
70498, 70547, 70548,
70549, 93880, 93882

14

Don’t perform unproven
diagnostic tests, such as
immunoglobulin G (IgG)
testing or an indiscriminate
battery of immunoglobulin

Diagnostic tests
CPT: 82701, 82784,
82785, 82787, 86005

ICD-9: 410.xx, 411.1,
411.81, 411.89
DRG 281-287
All beneficiaries except
those with a clear indication
(radicular symptoms,
*symptoms clearly of
herniated disc—radicular
pain

Herniated disc (omitting cervical):
ICD-9: 722.1, 722.2, 722.3, 722.5, 722.6,
722.7, 722.8, 722.9
722.70, 722.72, 722.73, 722.80, 722.82,
722.83, 722.90, 722.92, 722.93
Nor
Two occurrences within 30 days for
following ICD-9 (any combination):
ICD-9: 355.0, 355.7, 355.8, 355.9, 724.3,
724.4, 729.2

Individuals with a diagnosis
of sinusitis (acute or
chronic) –inpatient or
outpatient
ICD-9: 461, 461.x, 473,
473.x
All patients* with CHF
ICD-9: 428, 428.0, 428.1,
428.2, 428.3, 428.4, 428.9
428.2x, 428.3x, 428.4x AF
& Flutter
ICD-9: 427.3, 427.3x
Syncope
ICD-9: 780.2, 992.1 (heat),
337.01 (carotid sinus)

Traumatic brain injury
ICD-9: 850, 850.x, 850.xx,
851, 851.x, 851.xx, 852,
852.x, 852.xx, 853, 853.x,
853.xx, 854, 854.0, 854.0x,
854.1, 854.1x, 959.01
Within first 2 days
Low back pain
ICD-9: 721.3, 721.90,
722.10, 722.52, 722.6,
722.93, 724.02, 724.2,
724.3, 724.5, 724.6, 724.70,
724.71, 724.79, 738.5,
739.3, 739.4, 846.0, 846.1,
846.2, 846.3, 846.8, 846.9,
847.2
All beneficiaries

Allergic rhinitis
ICD-9: 477.0, 477.1,
477.2, 477.8, 477.9
Asthma
ICD-9: 493.0, 493.02,
493.9, 493.90, 493.92

100

ED Visit
CPT: 99281-99285

Hospitalization associated with ED or ED
up to 14 days before procedure,
ICD9: 430, 431, 43301, 43311, 43321,
43331, 43381, 43391, 43400, 43401,
43410, 43411, 43490, 43491, 4350, 4351,
4353, 4358, 4359,
436, 99702, V1254, 3623, 36284, 7802,
781xx, 7820, 78451, 78452, 78459, 781xx

15

E (IgE) tests, in the
evaluation of allergy.
Don’t perform imaging for
low back pain within the
first six weeks unless red
flags are present.184,186

MRI of the lumbar spine
studies with a diagnosis
of low back pain CPT
72148, 72149, 72158

Other allergies
ICD-9: 708.0, 995.3
Low back pain
ICD-9: 721.3, 721.90,
722.10, 722.52, 722.6,
722.93, 724.02, 724.2,
724.3, 724.5, 724.6, 724.70,
724.71, 724.79, 738.5,
739.3, 739.4, 846.0, 846.1,
846.2, 846.3, 846.8, 846.9,
847.2

NOT in 60 days preceding Lumbar Spine
MRI Therapies CPT: 97110, 97112, 97113,
97124, 97140, 98940, 98941, 98942,
98943.
NOT between 28 and 60 days preceding
Lumbar Spine MRI
Evaluation and management
CPT: 99210-99205, 99211 -99215, 9924199245, 99341-99345, 99347-99350, 9935499357, 99385-99387, 99395-99397, 9940199404, 99455-99456, 99499.
NOT in the preceding 90 days
(denominator)
Lumbar Spine Surgery
CPT: 22010-22865 and 22899.
NOT in preceding 365 days
ICD-9: 140-208, 230-234, 235-239;
304.0X, 304.1X, 304.2X, 304.4X, 305.4X,
305.5X, 305.6X, 305.7X, 344.60, 344.61,
729.2, 042-044, 279.3
NOT in preceding 45 days
All patients with prostate and breast cancer.
Trauma
ICD-9: 800-839, 850-854, 860-869, 905909, 926.11, 926.12, 929, 952, 958-959
NOT on the same claim
Intraspinal abscess
ICD-9: 324.9, 324.1

16

IVC filters to prevent PE

Any IVC filter
placement CPT Before
2012: 75940 In and After
2012: 37191
Renal/visceral
angioplasty or stent
placement with renal
atherosclerosis or
renovascular
hypertension diagnosis
in procedure claim CPT
35471, 35450, 37205,
37207, 75966, 75960
Calcitriol test CPT
82652

17

Renal artery angioplasty or
stent

18

Don’t perform populationbased screening for 25-OHvitamin D deficiency.4,187

19

Don’t do imaging for
uncomplicated headache.4

Brain CT or MR imaging
CPT: 70450, 70460,
70470, 70551, 70552,
70553

Uncomplicated headache
ICD9: 30781, 7840, 339xx,
346x

20

T3 testing for
hypothyroidism.4

Total or free T3
measurement in patients
with hypothyroidism.
CPT 84480, 84481

Hypothyroidism within 1
year (244xx), 1 year
look-back

ICD9: 4401, 40501, 40511,
40591

101

hypercalcemia, secondary
hyperparathyroidism, or other
hypercalcemia condition (sarcoidosis, TB,
or selected neoplasms) in claim, or CKD
history; no hypercalcemia diagnosis in past
30d ICD9: 27542, 58881, 1890, 1891,
1830, 135xx, 173xx, 174xx, 175xx, 188xx,
200xx, 201xx, 202xx, 203xx, 204xx,
205xx, 206xx, 207xx, 208xx, 01xxx
posttraumatic, thunderclap
headache diagnosis,
or diagnoses in claim
warranting imaging. ICD9: 33920, 33921,
33922, 33943, 4465, 78097,
V1254, 345xx, 800xx, 801xx, 802xx,
803xx, 804xx, 850xx, 851xx, 852xx,
853xx, 854xx, 870xx, 871xx, 872xx,
873xx, 781xx, V10xx, 3463x, 3466x,
7803x, 7845x, 9590x, 43xxx,
140xx-208xx, 230xx-239xx

102

